KARINA FINCATI Senior Researcher VenetoNanotech 7ProgrammaQuadro

9/9/2018 draft DOW14012009 V09
Questa è la versione html del file https://bur.regione.veneto.it/BurvServices/pubblica/Download.aspx?name=858_AllegatoA_214544.pdf&type=9&storico=False. Google genera

automaticamente le versioni html dei documenti mentre viene eseguita la scansione del Web.
Suggerimento. Per trovare rapidamente il termine di ricerca su questa pagina, digita Ctrl+F o ⌘-F (Mac) e utilizza la barra di ricerca.
Page 1
EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09
SEVENTH FRAMEWORK PROGRAMME THEME

[NMP / Integration of technologies for industrial applications /
Nano-Medicine]
Grant agreement for: Coordination and support action (ERA-NET scheme)
Annex I - “Description of Work”

Project acronym: EuroNanoMed
Project full title: EUROpean network of trans-national collaborative RTD projects in the
field of NANOMEDicine
Grant agreement no.: CSA-CA 234811 EuroNanoMed
Date of preparation of Annex I (latest version): January 12, 2009

Date of approval of Annex I by Commission: (to be completed by Commission)
List of beneficiaries
Benef Beneficiary name Beneficiary Country/ Date enter Date exit

iciary short name Region project project
n° (month n) (month n)
P1 CEA - Atomic Energy Commission CEA France 1 36
P2 Basque Ministry of industry ITT Basque 1 36
region
P3 Agencia Vasca de la Innovación, Innobasque INNOBASQUE Basque 1 36
Country
P4 Swiss National Science Foundation SNF Switzerland 1 36
P5 Federal Ministry of Education and Research BMBF Germany 1 36
P6 VDI Technologiezentrum GmbH VDI Germany 1 36
P7 Instituto de Salud Carlos III, ISCIII /Fundación para la ISCIII Spain 1 36
Cooperación y Salud Internacional Carlos III, FCSAI
P8 Agence Nationale de la Recherche, ANR ANR France 1 36
P9 National Office for research and technology NKTH Hungary 1 36
P10 Ministry of Health, The Chief scientist office, CSO-MOH Israel 1 36
P11 The Icelandic Centre for Research RANNIS Iceland RANNIS Iceland 1 36
P12 Latvian National Academy of Sciences LAS Latvia 1 36
P13 Senternovem The 1 36
SenterNovem
Netherlands
P14 National centre for research and development NCBIR NCBIR Poland 1 36
P15 FCT - National Science Foundation FCT Portugal 1 36
P16 National Authority for Scientific research ANCS Romania 1 36
P17 National Center for Programme Management CNMP Romania 1 36
P18 Swedish Research Council SRC Sweden 1 36
P19 VINNOVA VINNOVA Sweden 1 36
P20 The Scientific and Technological Research Council of TUBITAK Turkey 1 36
Turkey
P21 Science Council of Lithuania LSC Lithuania 1 36
P22 Veneto Region VED Veneto 1 36
Region
P23 Veneto Nanotech Veneto Veneto 1 36
Agency Region
P24 Ministry of Wallonia / Research and scientific MRW Wallonia 1 36
cooperation Directorate Region
Co-ordinator: P1 –Commissariat à l’Energie Atomique (CEA)
Name of the co-ordinating person: Dr. Pierre-Noël LIRSAC
E-Mail: Pierre-noel.lirsac@cea.fr Tel: +33 1 69 08 64 26 Mob:+ 33 6 77 7982 98 Fax: + 33 1 69 08 59 07
https://webcache.googleusercontent.com/search?q=cache:G6jcYisSAhgJ:https://bur.regione.veneto.it/BurvServices/pubblica/Download.aspx%3… 1/57
9/9/2018 draft DOW14012009 V09
Page 2
Table of content
PAGE
PART A
A1. Budget breakdown and project summary
A.1 Overall budget breakdown for the project 3

A.2 Project summary 3
A.3 List of beneficiaries 4
PART B
B1. Concept and objectives, progress beyond state-of-the-art, S/T methodology and work plan
B.1.1 Concept and project objective(s) 5

B.1.1.1 Nanomedicine: a challenge for Europe 5
B.1.1.2 Main objectives and long term vision 7
B.1.1.3 Strategic objectives of the EuroNanoMed initiative 8
B.1.2 Progress beyond the state of the art 10

B.1.3 S/T methodology and associated work plan 11
B.1.3.1 Overall strategy and general description - Risk assessment and contingency plans 11
B.1.3.2 Timing of work packages and their components 13
B.1.3.3 Work package list /overview 16
B.1.3.4 Deliverables list 17
B.1.3.5 Work package descriptions 18
B.1.3.6 Efforts for the full duration of the project 34
B.1.3.7 List of milestones and planning of reviews 36
B2. Implementation
B.2.1 Management structure and procedures 37

B.2.1.1 Organisation and structure of the management framework 37
B 2.1.2 Internal reporting decision making structures conflict management, moderation 40
B.2.2 Beneficiaries 41
B.2.3 Consortium as a whole 63
B.2.3.1 Contracting partners 63
B.2.3.2 Sub-contracting 63
B.2.4 Resources to be committed 64
B3. Potential impact 66
B.3.1 Strategic impact 66

B.3.1.1 Improve coordination and reduce overlapping and fragmentation 66
B.3.1.2 To achieve critical mass and insure a better use of limited resources 68
B.3.1.3 Sharing good practices in implementing common research programmes 68
B.3.1.4 To promote trans-national collaboration and generate new knowledge 70
B.3.2 Spreading excellence, exploiting results, disseminating results 70
B.3.2.1 Collaboration with European Technology platform in Nanomedicine 70
B.3.2.2 Collaboration with other specific European Stakeholders 71
B.3.2.3 EuroNanoMed website 71
B.3.2.4 Contributions to policy developments 71
Page 3
PART A
A.1.Budget breakdown and project summary
A.1 Overall budget breakdown for the project
9/9/2018 draft DOW14012009 V09
• Budget breakdown form (copy of A3.2 form of the GPFs). : to be added
A.2 Project summary
Nanomedicine is an emerging field with a large potential for developing public welfare and
economic growth. Critical issues for bringing up this potential in Europe concern especially
the maturity of the economic players and their capability to move effectively innovation from
knowledge to industrial technology and to clinical and public health applications. Industrial
players need therefore to collaborate closer with scientific partners and with clinicians. The
second issue is the ability of companies to establish multidisciplinary networks with the
research and the clinician communities, increasing their efforts towards biological preclinical
and clinical validations. This will shorten the delay for patients to benefit from the innovation
and increase the competitiveness of European actors.
Therefore EuroNanoMed targets the creation of a mechanism to support trans-national

collaborative RTD projects between academic laboratories, companies, especially SME’s, and
clinicians/public health setting, in the field of Nanomedicine, using a bottom up approach. In
consequence, EuroNanoMed will develop coordinated European-wide programmes based on
2 common joint trans-national calls and funding. The thematic of these two calls will focus on
the strategic research priorities of the European technology platform “Nanomedicine”:
diagnostics, targeted delivery and regenerative medicine.
EuroNanoMed achieves an effective critical mass: the 21 participating national/regional
programmes expect to dedicate significant budget to the calls, approximately 15-20% of the
sum of their national/regional Nanomedicine budgets.
The Long Term Vision of EuroNanoMed is the design of a European-wide integrated
programme with a coordinated funding. Potential scenario for implementation will be
delivered.
Page 4
A.3 List of beneficiaries

Benef Beneficiary name Beneficiary Country/ Date enter Date exit
iciary short name Region project project
n° (month n) (month n)
P1 CEA - Atomic Energy Commission CEA France 1 36
P2 Basque Ministry of industry ITT Basque 1 36
region
P3 Agencia Vasca de la Innovación, Innobasque INNOBASQUE Basque 1 36
Country
P4 Swiss National Science Foundation SNF Switzerland 1 36
P5 Federal Ministry of Education and Research BMBF Germany 1 36
P6 VDI Technologiezentrum GmbH VDI Germany 1 36
P7 Instituto de Salud Carlos III, ISCIII /Fundación para la ISCIII Spain 1 36
Cooperación y Salud Internacional Carlos III, FCSAI
P8 Agence Nationale de la Recherche, ANR ANR France 1 36
P9 National Office for research and technology NKTH Hungary 1 36
P10 Ministry of Health, The Chief scientist office, CSO-MOH Israel 1 36
P11 The Icelandic Centre for Research RANNIS Iceland RANNIS Iceland 1 36
P12 Latvian National Academy of Sciences LAS Latvia 1 36
P13 Senternovem The 1 36
SenterNovem
Netherlands
P14 National centre for research and development NCBIR NCBIR Poland 1 36
P15 FCT - National Science Foundation FCT Portugal 1 36
P16 National Authority for Scientific research ANCS Romania 1 36
P17 National Center for Programme Management CNMP Romania 1 36
P18 Swedish Research Council SRC Sweden 1 36
P19 VINNOVA VINNOVA Sweden 1 36
9/9/2018 draft DOW14012009 V09
P20 The Scientific and Technological Research Council of TUBITAK Turkey 1 36
Turkey
P21 Science Council of Lithuania LSC Lithuania 1 36
P22 Veneto Region VED Veneto 1 36
Region
P23 Veneto Nanotech Veneto Veneto 1 36
Agency Region
P24 Ministry of Wallonia / Research and scientific MRW Wallonia 1 36
cooperation Directorate Region
Page 5
PART B
B1. CONCEPT AND OBJECTIVES, PROGRESS BEYOND STATE-OF-

THE-ART, S/T METHODOLOGY AND WORK PLAN
B 1.1 CONCEPT AND OBJECTIVES
B 1.1.1 Nanomedicine: a challenge for Europe
Europe is facing strategic challenges in the field of health due to issues such as ageing population,
negative environmental effects on personal health and demand for improved personal healthcare. This
in turn to a dramatic modification of the healthcare system policy and it will be important for Europe
to cope with these new issues. Healthcare expenditures presently account for 10% of gross domestic
product (GDP) in industrialised countries and are expected to grow at an average rate of 6% per year
in the future. So it is important to be prepared for this new revolution by anticipating it through
advanced research and innovation that will meet the aforementioned issues at moderate costs.
Simultaneously, it is understood that these issues will create a new market that will impact the
economy of the European countries. Europe has already taken into account these strategic issues
through the technological platforms (ENIAC www.eniac.com, smart systems: www.smart-systems-
integation.org, and Nanomedicine: cordis.europa.eu/nanotechnology/nanomedicine.htm).
One way to meet these challenges is to propose some breakthrough using the enormous potentialities
exhibited by the nanotechnologies that define a new scientific field referred to as Nanomedicine where
it is envisioned to proposed new approaches to better predict, prevent diseases and to optimize the
therapy processes. These two concepts will drastically improve the quality of life of citizen and will
minimize the healthcare costs. Simultaneously, they will create a significant industrial market where
Europe has to take an important part.
9/9/2018 draft DOW14012009 V09
Figure 2: Nanomedicine impact and main research topics.
Page 6
The emergence of Nanomedicine translates into new approaches concerning the research organization,
the bridge between academic research, industries and clinical applications. At early stage, it is
important to have a high flexibility to facilitate cross fertilization between the different actors and to
accelerate the chain value process from the research concept to the product that will be used ultimately
by patients. Consequently, the bridge between the different actors will consolidate and improve the
competitiveness of the European industry that will be very important in the worldwide competition in
this sector. These two issues will largely benefit from the ERA-NET scheme that will be additionally
complementary with respect to other European initiatives.
European countries are investing substantial amount of resources into the development of a
nanotechnology industry. Nanomedicine, the application of nanotechnology to healthcare, promises
significant progress in the fields of medical diagnosis, therapy and monitoring leading to an affordable
higher quality of life for everyone. Most market forecasts for nanotechnology in general predict an
average yearly growth rate of 10-20% for the next ten years1. No clear data are available for
Nanomedicine. Nevertheless, the growth rate of the medical device industry is close from 10% per
year, and the investment of health to the EU economy is important2. These rates are 3 to 5 fold higher
than the present and expected GDP growth rate for EU Member States (MS). Consequently, providing
a MS’s support to application driven RTD projects in Nanomedicine should provide a global economic
return for the EU.
Even if there is a consensus on the vast potential of Nanomedicine for developing public welfare and
economic growth, there is evidence that the field has rather special needs for bringing up this potential.
Critical issues in Europe concern especially
- The maturity of the economic players within the Nanomedicine field and the capability to move
effectively innovation from knowledge to industrial technology and to clinical and public
health applications. Industrial players need therefore to collaborate closer with scientific partners
and with clinicians: to this respect the flexibility of the ERA-NET scheme is an asset.
- The ability in the harsh global competition, to have companies networking in multidisciplinary
small teams with the research and the clinician communities and increasing their efforts
towards biological preclinical and clinical validations. This will already shorten the delay for
patients to benefit from the innovation and increase the competitiveness of European actors.
Nanotechnologies have been identified as one of the thematic priority areas for the European Union
(Barcelona European Council). The communication from the Commission “Towards a European
strategy for nanotechnology” (COM 2004-338 final) as well as the action plan for Europe (COM
2005-243 final) have pointed out the potential of nano technologies, and stressed the importance of
solid and nationally funded research efforts allowing cross-border co-operation between the best
researchers from public and private sectors.
Each country has taken somewhat different approaches in their national programmes aiming at
supporting industrial RTD in the field. Despite the existence of some similarities between these
national programmes, the overall impact is therefore sub-optimal. The national feedback provides
evidence that enabling fundamental research to enter into preclinical and first clinical stages is a
critical issue. This issue has been addressed with a very mitigated result at national level because in
the very specific domain of Nanomedicine there are too few players at national level. Achieving such a
critical mass taking benefit from complementarities between European countries is today realistic
because the National programmes have difficulties to support Trans-national projects. This is the
main goal of the EuroNanoMed ERA-NET initiative.
Moreover, Nanomedicine is often not the main focus of the national calls and thus border line and in
competition with many other fields. In addition, the 7th Framework Programme (FP7) is limited in
funding and many good projects can’t be supported. Optimisation of resources, achieving a critical
mass and non-duplicating but complementing the FP7 activities has to be implemented.
1 The economic development of nanotechnology – an indicator based analysis – Dr. A Hulleman - 28 Nov 2006
2 Suhrcke M et al. The contribution of health to the economy in the European Union. DG SANCO, 2005.
9/9/2018 draft DOW14012009 V09
Page 7
Thus there is a strong need to create a mechanism to support trans-national collaborative RTD
projects between academic labs, companies, especially SME’s, and clinicians/public health, in
the field of Nanomedicine, using a bottom up approach.
The Eureka programme doesn’t seem to meet these requirements. This programme is really a
superposition of national programmes, preserving their relative independence. Moreover not all
national agencies do support financially their national participants. In addition, no support to the
matching of partners is provided.
For that purpose, EuroNanoMed is a major opportunity for the European enterprises and the research
and clinicians communities to take benefit from the flexible co-ordination of several existing
national funding programmes to enlarge their possibilities for partnerships, to fruitful cross-
border partnerships. A similar multidisciplinary translational approach in the field with an
international focus as the one developed in EuroNanoMed does not yet exist. This initiative will
bring together the academic, the clinical/public health and the industrial research teams to
develop innovative diagnostic and therapeutic solutions for the patient, thus enhancing the
competitiveness of the European health industry.
Today, such a coherent network (EuroNanoMed) of national funding programs could really strengthen
the European Nanomedicine sector and prepare the following step, meaning a truly integrated and
sustainable common trans-national RTD programme in the field.
B 1.1.2 Main Objectives and Long Term Vision
The main objective of EuroNanoMed is to foster the competitiveness of European Nanomedicine

actors, supporting both:
1/ the transfer between partners from academia, industry, and clinical/Public health setting
2/ the research of industrial companies in their multidisciplinary trans-national strategic
partnerships with academics and clinical/Public health care setting, to achieve innovative
RTD projects in Nanomedicine.
Significant industrial participation in these RTD projects will therefore be a crucial precondition to
achieve this objective. This focus is in line with the new strategy of the NMP programme which is
currently developed by the Directorate for Industrial Technologies of the European Commission
together with the member states and will support the Strategic Research Agenda of the European
Technology Platform (ETP) for Nanomedicine. To support these strategic partnerships between
industry on the one side and academics and clinicians on the other side, EuroNanoMed will develop
coordinated European-wide programmes based on common joint calls and funding. The
thematic focus of these calls will be based on the three strategic research priorities of the ETP
for Nanomedicine, namely
- diagnostics,
- targeted delivery,
- regenerative medicine,
as defined in the Strategic Research Agenda and the vision document issued by the ETP. It will
thus be based on the research priorities of the major European stakeholders. A constant dialogue
between the Commission, the NSC of the ERA-Net and the ETP will be established to assure
complementary thematic priorities and to avoid funding of identical research topics.
The Long Term Vision lagging behind EuroNanoMed is the concept of a European-wide fully
integrated programme with coordinated funding. EuroNanoMed is a first step to meet this goal
within the ERA landscape.
EuroNanoMed will use a step by step approach based on 2 common joint trans-national calls
(JTC) for collaborative RTD projects, implementing progressively the opening of the national
Page 8
programmes to support trans-national RTD partnerships between academics, companies, and

clinicians in the Nanomedicine area. These 2 calls will be more and more integrated.
This approach allows checking progressively the identified solutions to overcome the barriers and
hurdles issued from the analysis of the existing programmes
• based on the systematic exchange of information between the partners,
• and taking benefit from the lessons learned from existing ERA-Nets and
experience acquired during the calls.
EuroNanoMed calls programme is conceived as a trans-national programme based on a
9/9/2018 draft DOW14012009 V09
multinational common basis, all partners doing at the same time, the same activities altogether.
B 1.1.3 Strategic Objectives of the EuroNanoMed initiative
The proposed network has the following strategic objectives:

• Co-ordination and co-operation of the national Nanomedicine programmes of the 18 participating
countries/regions comprising a budget envelope amounting approximately 40-60 M€. This
corresponds approximately to 10-15% of the sum of their national/regional budget specifically
dedicated to support Nanomedicine applications.
• Joint funding of common trans-national innovative projects of RTD involving partnerships
between industrial companies, clinicians, and academics including a joint approach for project
evaluation and selection. These calls aim for significant participation of industrial partners,
especially SMEs and focus on the strategic research priorities of the ETP Nanomedicine as
described in Section B1.1.2
• Systematic benchmark of national programme management approaches in partnering
countries/regions, definition of best practices,
• Development of joint strategies for improving and accelerating the technology transfer of
diagnostic and therapeutic solutions from academy and clinicians to companies and to patient
applications, using trans-national co-operations,
• Identification and addressing of non-technological innovation barriers (regulatory affairs, etc.) in
terms of later exploitation and market access for companies in the field of Nanomedicine,
• Delivery of essential contributions to achieve a safe and responsible implementation of
Nanomedicine within the frame of the RTD projects funded in EuroNanoMed.
These objectives will be delivered through five work packages, with the following specific benefits:
Work package A (WPA): Systematic mapping of the ongoing programmes and strategic agenda
for joint activities
• Systematic benchmark of the programmes involved in EuroNanoMed
• Provides information, feedback and learning opportunities for the national managers to
define and adopt best practices
• Provides national government officials with high quality policy information, developing
their commitment to the strategic development of the ERA-Net
The primary objective of this WP is to share the domain of knowledge on the opportunities and
barriers to increase co-operation across national boundaries. The second is to develop a strategic
Agenda for the implementation of the EuroNanoMed activities and for the possible future programme
beyond the end of EuroNanoMed.
Work package B (WPB): Establishment of the framework for the EuroNanoMed common RTD
programme with joint trans-national calls
To provide relevant framework on the joint trans-national calls for proposal organised within
EuroNanoMed for the actors of RTD in Nanomedicine
Page 9
• To develop common and appropriate tools and procedures for the selection of
multinational projects and for the monitoring and assessment of multinational procedures
• To establish common evaluation procedures according to international peer reviewed
evaluation, a panel of Peer Reviewers of academics, industrials and clinical/Public health
will be nominated by the NSC Call Steering Committee. This panel will be helped in their
evaluation by external anonymous reviewers.
• To assess the implementation of joint trans-national calls for proposal.
• To ensure that the scientific and structural scope of the calls are meeting the industrial,
clinical/public health and scientific needs of the Nanomedicine field, and will focus on the
strategic research priorities of the ETP Nanomedicine as described in section B.1.1.2.
Work package C (WPC): Implementation of the common joint trans-national call(s) for projects
• To provide knowledge and opportunities for enterprises and labs to match with their
potential European partners in order to answer to the EuroNanoMed Calls for projects
• To encourage the potential partners to take part to the EuroNanoMed common joint trans-
national call(s) for projects
• To implement the common joint trans-national Call(s) for projects,
• To implement international peer reviewed evaluation through a panel of Peer Reviewers
nominated by the NSC Call Steering Committee and supported for the evaluation process
by external anonymous reviewers.
Upon prioritization, the EuroNanoMed calls for proposals will reinforce the implementation of the
strategic research agenda3 (SRA) of the European Technology Platform Nanomedicine as described in
Section B1.12 and aim for significant industrial participation, especially of SMEs. Minimum
conditions in order to guarantee trans-nationality and a substantial representation of industrial partners,
will be discussed during the preparation of each call.
9/9/2018 draft DOW14012009 V09
Work package D (WPD): Non-technological innovation barriers

The development and introduction of Nanomedicine is entailing revolutionary changes in diagnostic
and therapy fields. As these advancements have overcome the classical separation between medical
and pharmaceutical products, the scientific community and institutional bodies have to face some
important issues due to the lack of official regulatory aspects of the matter. The lack of specific
protocols of practices and standard criteria, of a recognized international terminology and the potential
inapplicability of traditional regulations for these brand new Nanomedicine products, are turning out
to be imponderables that may considerably hinder industrial R&D and delay market access of
innovative products. Therefore, it is essential to provide a first national and EU-wide survey on non-
technological innovation barriers (especially regulatory affairs) in view of later exploitation and
market access for companies. As these questions are today more and more directed at the European
level (EMEA) in a global European market it is meaningful and necessary to consider this issue at
a European rather than at a national level. This issue is critical to avoid any loss of resources and
efforts for MSs, companies and research/clinical communities and to ensure that new products -
supported through the EuroNanoMed calls - could get fast market authorization to quickly benefit
the patient.
Furthermore, when talking about new drugs and technologies, aspects like social risk perception,
bioethical implications and safety of end users and patients have to be considered. These points are
fundamental for a new discipline like Nanomedicine where a common coordination action is still
missing. Thus, a second part of WPD will consist in developing guidelines for ELSA issues,
applicable to the projects funded in the EuroNanoMed calls that could be considered acceptable
by all stakeholders.
Detailed objectives of WPD are:
• Identification and structuring of possible problems associated with non-technological
innovation barriers
• first national and EU-wide survey of non-technological innovation barriers (especially
regulatory affairs) in view of later exploitation and market access for companies
Page 10
• Provide feedback relevant information to WP B

• Provide knowledge and opportunities to overcome non-technological innovation barriers
• Enhance interactions with relevant stakeholders together with the ETP Nanomedicine and
EMEA
• Implement an inventory of the most relevant issues related to general safety aspects at a
European level (in collaboration with the ELSA boards of the ETP Nanomedicine, Nano2Life
network and the FP7 CSA “roundtable in Nanomedicine”) and comparison with North
America and Japan
• Establish a synthetic report summarizing the analysis, conclusions and recommendations with
Nanomedicine
Work package E (WPE): Management and support

Establish a practical infrastructure that will manage all of the administrative, technical, communication
and economic aspects of the ERA-Net and initiate strategic activities.
• Develop a sustainable network of influential national government representatives with
policy responsibility for biotechnology involvement in European competitiveness of
industry.
• Establish an External Advisory Board
• Prepare annual ‘major’ workshops and progress reports
• Make the main results and lessons learned accessible to the relevant audiences
In order to assess the progress achievements made in the implementation of the whole EuroNanoMed
programme, the following milestones have been established addressing respectively:
- Shared common understanding on EuroNanoMed programme and rules (Milestone 1 - month
1),
- A common understanding of the partnering programme rules and practices, leading to the
elaboration of a common strategic agenda / road map of EuroNanoMed activities (Milestone 2
- month 3)
- The go/no go decision to launch the 1st joint trans-national call (Milestone 3 – month 4)
- The go/no go decision to launch the 2nd joint trans-national call (Milestone 4 – month 15)
- The conception and design of a post EuroNanoMed programme frame (Milestone 5 – month
33)
B 1.2 CONTRIBUTION TO THE COORDINATION OF HIGH QUALITY

RESEARCH
The objective of EuroNanoMed is to have a clear added value for the field of Nanomedicine. As a
summary this value is expected to lay on:
• The ability to support trans-national projects in the field. EuroNanoMed creates a mechanism to
9/9/2018 draft DOW14012009 V09
support Trans-national collaborative RTD projects using a bottom up approach and the support to
small size projects to meet the specific needs in the field of Nanomedicine. This mechanism is
complementary to FP7 and national programmes. National programmes have difficulties to support
Trans-national projects, and FP7, is limited in topics and in funding, and many good projects
cannot be supported.
• The complementation of expertise and competences in one given country with the competence
existing in an other one, making it possible to implement together more ambitious projects
targeting the excellence and taking benefit from synergies.
• Today, each country supports national projects on the basis of a national selection. Establishing
an international selection process will enlarge the national pools of experts to a European one,
effectively contributing to increase the equality of the expertise and the selection process. Then
only the best projects will be selected and supported, according to the procedures and criteria
commonly defined and agreed in WPB, and implemented in WPC.
10
Page 11
• An impulse towards the applications of Nano biotechnology to medicine to accelerate the

maturation of this field. As the common joint trans-national calls will enhance the partnerships
between academic, industrial, and/or clinical/public health teams, the priorities of the strategic
agenda defined in WPA will be used to define the focus of the calls. These priorities will endorse
the EAB expertise and the conclusions of the workshop to gain insight in strategic priorities.
Moreover, agenda from the European Technology Platform for Nanomedicine will be also of
great help to define the focus of the calls, as one member of the EAB will be also a member of
this platform. Based on breakthrough concepts and focusing the translational research, these calls
will enable innovation to enter into proof of concept, clinical research, preclinical and first
clinical stages and lead to develop and offer new capabilities and benefits.
• The avoidance of Public Health risk, the promotion in the near future of good clinical practices,
clinical expertise and the implementation of international multi-site trials as a result of the
coordination through common joint trans-national calls
However, due to the large number of partners, the achievement of this added value is closely related and
dependant from the effectiveness and the quality of the coordination mechanisms established in the
EuroNanoMed consortium, as detailed in part B 2.1.
B 1.3 QUALITY AND EFFECTIVENESS OF THE COORDINATION

MECHANISMS AND ASSOCIATED WORK
B 1.3.1 Overall strategy and general description:
The WPA corresponds to analysis and conception tasks, implemented first in the early stage (Months
1-9) and then updated to keep the information pertinent until year 3. The Network Steering Committee
(NSC) (senior representatives of national government/agencies in charge of programme policy) will be
deeply involved in the preparation of road map and action plan of the strategic activities.
At the end of WPA, a good knowledge of the partnering programme and a vision of their national
RTD actors and environment will be gained. Moreover, a strategy and roadmap will be implemented
and regularly updated using the lessons learned in WPB and WPC, the input from the Executive
Advisory Board, the ETP Nanomedicine, the FP7 calls and other relevant sources. A structured
vision of the future trans-national EuroNanoMed RTD programme for collaborative projects
targeting a more integrated and sustainable ERA-NET will be proposed. Potential scenarios for
implementation will be suggested.
Two common joint calls for proposals will be designed and launched respectively during year 1 and
end of year 2
The WPC focuses the design, processes and procedures of the 2 calls as well as their implementation.
• In particular, WPC will establish common evaluation procedures according to international peer
reviewed evaluation based on a panel of Peer Reviewers composed of academics, industrials and
clinical/public health experts nominated by the NSC Call Steering Committee. This panel will be
helped in their evaluation by external anonymous reviewers.
• The WPC is also dedicated to the implementation of the calls. Our goal is to launch the first
call during the first year (month 5-7). After the first call, milestone 4 (meeting M6) will lead to a
common and open decision (EB and NSC) to continue with a second call for proposal (end of year
2).
9/9/2018 draft DOW14012009 V09
11
Page 12
WPD addresses non-technological innovation barriers and safety aspects specific to the field of
Nanomedicine. During the ERA-Net EuroNanoMed activities, WPD will support identifying and
addressing of national and EU-wide non-technological innovation barriers. This will be done in close
collaboration with relevant internal and external stakeholders, such as, for example, the ETP
Nanomedicine and EMEA. In a first step, these activities will lead to an expert workshop (Month 12).
The results of the workshop will be fed back within the first common joint call. Furthermore, a
market-oriented survey followed by a synthetic report will treat selected problems of non-
technological innovation barriers (year 3). This issue is really essential to ensure that the
development of new products, supported through the EuroNanoMed calls, could reasonably get
market authorization.
Finally, WPD will review ethical and safety issues raised by Nanomedicine to foster exploitation and
to inform relevant stakeholders involved in regulations and reimbursement. This is essential to
minimize the possible controversies about potential applications funded through the
EuroNanoMed calls for projects.
The WPE aims to establish a dedicated management resource for the whole project and develop
the necessary infrastructures (communication, join secretariat, web site, legal and financial
tools…etc.). Within the 4 first months, the joint secretariat and all the networking tools will be
established: the EB, the NSC, the EAB, and the support to WP and tasks leaders.
The main risks that may reduce the impact of the EuroNanoMed ERA-NET are relevant to the
implementation of the 3 pilot trans-national joint Calls for Proposals. In order to reduce these risks, the
consortium management will adopt the following strategies:
☞ Difficulties due to cultural differences and /or changes in national political priorities, and /or
lack of funding from one country.
Open communication and systematic exchange of information between the partners will be employed.
To minimize the risks, some of the earliest tasks (WP1) aim at providing information, comparison,
feedback and learning opportunities for the national programme managers as well as for the higher
government officials, in order to develop their commitment to the strategic development of this ERA-
NET and to develop a common vision on current and future research and development priorities.
☞ Difficulties due to a lack of funding from one country. The availability of national public
funding is of crucial importance for the success of the Initiative. Thus, (Ref Consortium Agreement
Art.II) the Programme owners responsible of R&D funding programme commit themselves to do as
much as possible to provide funding for projects presented and selected in the frame of the Initiative.
However the possibility and conditions of transfer of tasks due to case of Force Majeure is foreseen in
this document.
☞ National policy makers may not be able to consider trans-national RTD progress.
The Network Steering Committee (NSC) members are of senior representatives in charge of
programme policy of national government/agencies. Inter alia this committee will be involved (Task
A.2) in the preparation and the endorsement of the road map and the action plan for the joint activities
which is one of the early tasks. In addition, one of the early tasks (Task A.1) is a study on the enablers
for trans-national RTD progress.
☞ A low number of projects is submitted within the pilot trans-national joint Call for Proposals.
Before each Call for Proposals and following the action plan defined previously, dedicated
dissemination and publicity workshops will be organised systematically (Task C.3) in collaboration
with the European Technology Platform and information related to the call disseminated at national
and European level.
12
Page 13
B 1.3.2 Timing of work packages and their components:
The EuroNanoMed co-ordination activities and management functions will be organised into five
work packages.
☞ Work package A: Systematic mapping of the ongoing programmes and strategic agenda for
https://webcache.googleusercontent.com/search?q=cache:G6jcYisSAhgJ:https://bur.regione.veneto.it/BurvServices/pubblica/Download.aspx%… 10/57
9/9/2018 draft DOW14012009 V09
joint activities
The primary aim of WPA is to provide information and systematic joint benchmarking activities
on partnering programmes and the identification of complementarities and barriers, suggesting
solutions to overcome them. This will start immediately and will generate an essential input for the
national government officials with high quality policy information, developing their commitment to
the strategic development of WPB and WPC. This will be a basis for the definition of the strategic
agenda road map of EuroNanoMed activities.
There will be 3 main tasks:
• National information exchange: an inventory will be made on the characteristics, processes…of
the programmes partnering in EuroNanoMed a state-of-the-art of the partner’s national
programme (area)s, regularly updated. The tool has to be defined as a prerequisite (task A.1) in
Month 1.
• To identify enablers to trans-national RTD programmes and suggest how to overcome them;
• To define the best trans-national coordination practices;
The common strategy will be regularly updated, combining the input from the possible evolution of
the national programmes, the update of the strategic research agenda of the ETP, the input from the
Executive Advisory Board, the needs of the Nanomedicine actors and stakeholders, and the topics of
the FP7 calls.
The last task of WPA will take benefit from all the experience and lessons learned from other WPs to
design a proposal for a future European programme on Nanomedicine beyond the end of
EuroNanoMed.
☞ Work package B: Establishment of the framework for the EuroNanoMed joint trans-national
calls
Planning and executing trans-national funding activities require agreements on topics and on all
implementation and administrative issues. Then, WPB will provide the partners with a strong,
commonly agreed contractual framework as well as a joint funding scheme. This contractual
framework has obviously to be consistent with national legal applicable rules.
To develop this contractual framework, we will take benefit from pre-existing processes and
documents from various running programmes as a basis to be adapted (because no one seems to meet
all the potential requirements envisaged for EuroNanoMed), but in addition we will have to develop
specific ones (e.g. selection criteria and guidelines for evaluators…etc). Based on the results of WPA
and on lessons learned from other ERA-Nets, there will be three main tasks:
• To benchmark the joint trans-national calls organised in other ERA-NETS, as a preliminary task,
• To design the contractual framework and procedures for the joint trans-national calls, to be done
before the implementation of each joint trans-national call (WPC); including the design of the
international peer review common evaluation procedures based on a Panel of Peer Reviewers
including both academic, clinical/public health and industrial experts, nominated by the Call
Steering Committee, and helped in their evaluation by external anonymous reviewers;
• To analyse the feed back from the 1st trans-national call, to be used as an input for the 2nd joint
trans-national call.
☞ Work package C: Implementation of trans-national Call for Projects

The objective of WPC is to implement 2 successive common joint trans-national calls for project
proposals. Based on the process, procedures and documents defined in WPB and the analysis of the
13
Page 14
lessons learned the step by step process adopted in this WPC, allows the Network Steering Committee
to be proactive in the process of national/regional programmes integration. There will be 3 main tasks:
• The set up and implementation of a dedicated call office
• Implementation of the common joint trans-national call for project proposals according to the
roadmap defined in WPA and the framework adopted in WPB. This will include the
implementation of the common international peer reviewed evaluation procedure designed in
WPB.
• Dissemination activities to draw attention to EuroNanoMed calls when the calls will be launched
☞ Work package D: Non-technological innovation barriers

The main tasks of WPD will be to take into account and address non-technological innovation
barriers for later industrial exploitation and market access as well as concerns about safety,
ethical and social aspects of Nanomedicine. Within a global European market directed at the European
level (EMEA) it is essential to address this issue at a European rather than at a national level. These
activities will be carried out in close collaboration with WP1. The work package consists of three main
tasks:
• Identification, structuring and prioritising the non-technological innovation barriers for an
exemplary subfield of Nanomedicine (Diagnostics) by the way of an expert workshop, and
common work with stakeholders, the ETP Nanomedicine, the EMEA …
• Implement a Market-oriented Survey on the same subfield to suggest options to overcome these
barriers.
• Mapping of Nanomedicine related safety issues
9/9/2018 draft DOW14012009 V09
☞ Work package E: Management of EuroNanoMed and support
The Management of the coordination is a task to be implemented the whole duration of the
EuroNanoMed consortium. Specific infrastructure to run common activities, mainly the set up of an
internal and external Website, will be established and the EAB set in place.
Details regarding the timing and components of the different WPs are summarized in the following
Gant diagram.
14
Page 15
15
9/9/2018 draft DOW14012009 V09
Page 16
B 1.3.3 Work package list / overview:
Work- Work package title Type of Lead Person- Start End

package beneficiary months month month
activity
N° N°
A Systematic mapping of the ongoing COORD P18 16,3 1 34

programmes and strategic agenda for
joint activities
B Establishment of the framework for the COORD P7 33,5 2 34

EuroNanoMed common RTD
programme with joint trans-national
calls for proposals
C Implementation of Joint trans-national COORD P3 44,3 3 34

Calls for Proposals
D Non-technological innovation barriers COORD P6 27,1 1 36
E Management and support MGT P1 24 1 36
TOTAL 145,20
16
Page 17
B 1.3.4 Deliverables list:
Deliverable Deliverable name WP Lead Estimated Nature (2) Dissem.

N° n° beneficiary person.month level
n° (3)
A1 Questionnaire for the information exchange (Kick off meeting) A 17 3.3 O PU

A2 Reports on the national programmes A 17 3 R PU
A3 Identification of RTD priorities and barriers for EuroNanoMed joint activities A 14 1 R PU
A4 Strategic Agenda for EuroNanoMed joint activities A 14 2 R PU
A5 Conclusions of the workshop WS2 to gain insight priorities for JTC-2 A 11 3 R CO
A6 Conclusions of the meeting M9: EuroNanoMed future programme A 14 1 O CO
B1 Definition of procedures for the joint trans-national calls B 8 2.1 O CO
B2 Launch of the first Joint Trans-national Call (JTC1) B 7 8.2 O PU
B3 Selection of the external experts panel for peer review C 8 2 O CO
B4 Report on the analysis and lessons learned from the joint trans-national call results B 15 3 R CO
B5 Launch of the second Joint Trans-national Call (JTC2) B 7 7 O PU
C1 Set up of the trans-national call office C 23 4 O PU
C2 Results of the first joint trans-national call for proposals C 23 7.1 O PU
C3 Results of the subsequent 2nd joint trans-national call for proposals C 23 7.1 O PU
D1 Overview of the most relevant documents on Nanomedicine related Safety Issues D 23 2 R RE
D2 Synthetic report for safety issues, summarizing the analysis, conclusions and D 13 4 R CO
recommendations
D3 Expert workshop D 6 3 O RE
D4 Report and conclusions of the results of the expert workshop as an input for participants in D 6 3 R CO
the second trans-national call for proposals
D5 Market-oriented survey on regulatory affairs with respect to diagnostics and molecular D 6 3 R CO
imaging
D6 Synthetic Report of the Market-oriented Survey and the Expert Workshop on regulatory D 6 3.4 R PU
affairs
E1 Establishment of the Executive Board (EB) E 1 0.5 O CO
9/9/2018 draft DOW14012009 V09
E2 Establishment of a Joint Trans-national Call Secretariat (JTCS) E 1 0.5 O CO
E3 Establishment of a Network Steering Committee (NSC) E 1 0.5 O CO
E4 Website E 21 2 O PU + CO
E5 Establishment of the EAB E 20 2 O CO
E6 Periodic project reports E 1 5 R PU
E7 Progress/activity report and financial report E 1 9.5 R PU
E8 Publishable final report E 1 4 R PU
(2): [R: report; D demonstrator; O: Other]
(3): [PU: Public; PP Other programme participants; RE Restricted to a group specified by the consortium; CO: only for members of the consortium]
17
Page 18
B 1.3.5 Work package descriptions:
Work Package A: Systematic mapping of the ongoing programmes and strategic agenda for
joint activities (WPL: /Sweden Partner 18)
Work package WP A Start date or starting event: Kick off meeting , January
number 2009 (month 1)
Work Package title Systematic mapping and benchmarking of the ongoing programmes
Activity type COORD
Innoba MOH- RANN
Participant CEA ITT
sque
SNF BMBF VDI ISCIII ANR NKTH
CSO IS
LAS Senternovem
Participant n° 1 2 3 4 5 6 7 8 9 10 11 12 13
Person-months 0,1 0,1 0,1 0,1 0 0,1 0,1 0,1 0,1 0,1 3 0,1 0,1
NCBI VINN TUBIT Ven.
Participant R
FCT ANCS CNMP SRC
OVA AK
LSC VED
Nanot.
MRW
Total
Participant n° 14 15 16 17 18 19 20 21 22 23 24
Person-months 4 0,1 0 6,3 1,2 0,1 0,1 0,1 0,1 0,1 0,1 16,3
Objectives :
• To create an inventory of the partner's national/regional programs in Nanomedicine. The
results serve both for strategic and joint activities within the ERA-net itself and for a possible
cooperation beyond.
• Analysis of the barriers that may exist in different countries opening participating national
programmes to international co-operation and/or engaging in common trans-national
programmes with other countries
• To establish a strategic agenda for the EuroNanoMed activities.
Task A.1: Information Exchange on partnering programme (Task Leader: Romania – Partner
P17)- (Months 0-2)
Information will be gathered on national programme implementation processes. The scope of the task
consists of the different funding approaches for Nanomedicine actors (private and public) in Europe
and their structures/processes and will include the status and the national capabilities and perspectives
of financing “Nanomedicine” in national projects.
For an easy, comprehensible way of data exchange/processing, the TL will propose a common
electronic format/questionnaire available on the EuroNanoMed website, where each partner will
upload relevant information about his programme. This information to be finalized during the Kick-off
meeting, will include
- Elements on national/regional organisational policy in project financing,
- Legal and administrative framework and conditions for eligibility and funding
- Are there priorities/impossibilities in funding to industry/academy/ hospitals?
- Project evaluation policy
- IPR issues in funded projects
- Budgeting, cost models
- Timing
- Language
- Organisation of the programme management
- Monitoring and follow-up of the programme
- Information dissemination
- Networking and partnering activities
- Workshops and training
…etc
18
Page 19
9/9/2018 draft DOW14012009 V09
The result will be an analysis of best practices as an input for the preparation of the EuroNanoMed
calls and integration of EuroNanoMed activities in national programmes. Web addresses of relevant
sources of information in English will be provided by national authorities and organizations. On the
basis of the analysis of the collected data, the TL will prepare the final task report to be discussed
during the M2 meeting (Month 3) and to be published on EuroNanoMed Website.
As the EuroNanoMed website will only be available on month 5, the TL will provide in-between an
electronic tool for starting this preliminary task.
Task A.2 Analysis of complementarities between partners and barriers for EuroNanoMed
activities. Strategic Agenda for EuroNanoMed joint activities. (Task Leader: Poland – Partner
14) (Month 3)
In this subtask, on the basis of the result of task A.1, and the experience in other ERA-nets, the task
team will identify the complementarities between partners and barriers for co-operation. Possible
solutions for overcoming the barriers will be systematically analysed. The task team will summarize
the conclusions in a conclusion report delivered Month 4. The preliminary conclusions will be drawn
during the M2 meeting (month 3) and a strategic agenda for EuroNanoMed activities suggested.
The completion of this task will lead to a better understanding of practices by the different partners
and higher quality implementation of the EuroNanoMed project. The assessment of best practices will
be part of the plan for the trans-national common joint calls programme practices.
Combining the input from the possible evolution of the national programmes, the update of the
strategic Research Agenda of the ETP, the meeting M9 (month 34-milestone 5) will propose possible
future European programmes beyond the end of EuroNanoMed activities.
Task A.3: Organization of a workshop (WS2) to gain insight in strategic priorities on evolving
Nanomedicine needs for the second call. (Task Leader Iceland – Partner 11) - (Month 13)
This task involves an analysis of the evolving field of Nanomedicine to ensure that the scope of the
EuroNanoMed calls are kept in line with the academic, industrial, health, and clinical needs, as
Nanomedicine develops during the time frame of the ERA-NET. This will be implemented through a
workshop, bringing together scientists from industry, academia or clinical background (18 experts, the
EAB members and two persons from partner 11). Breakout sessions will give insights on a possible
strategic priorities concerning actions, training or research in this field. The analysis of the first joint
trans-national call will map strengths and weaknesses of the European community in Nanomedicine
pointing out the relevant areas to be addressed in the following call.
Deliverables
A1 questionnaire for the information exchange (Kick-off meeting)
A2 Reports on the national programmes (Month 4 )
A3 Identification of RTD priorities and barriers for EuroNanoMed joint activities (Month 3)
A4 Strategic agenda for EuroNanoMed joint activities (Month 3)
A5 Conclusions of the workshop WS2 to gain insight priorities for JTC-2. (Month 14)
A6 Conclusions of the meeting M9 : EuroNanoMed future programme (Month 33)
Milestones and expected results

Milestone 1: kick off meeting : Shared common understanding on EuroNanoMed programme
and rules.
Milestone 2: meeting M2 (Month 2) : A common understanding of the partnering programme
rules and practices, leading to the elaboration of a common strategic agenda / road map of
EuroNanoMed activities (2 days meeting).
19
Page 20
Work Package B: Establishment of the framework for the EuroNanoMed common RTD
(WPL: Spain – Partner P7)
Work package WP B Start date or starting event : month 2

number
Work Package title Establishment of the framework for the EuroNanoMed common RTD
Activity type COORD
Innoba MOH- RANN
Participant CEA ITT
sque
CSO IS
LAS Senternovem
9/9/2018 draft DOW14012009 V09
Participant n° 1 2 3 4 5 6 7 8 9 10 11 12 13
Person-months 15,
0.5 0.1 1.5 0.5 0 0.5 2 5.1 0.5 0.5 0.5 0.5 1.0
Participant R
FCT ANCS CNMP SRC
OVA AK
LSC VED
Nanot.
MRW
Total
Participant n° 14 15 16 17 18 19 20 21 22 23 24
Person-months 0.5 3.0 0 0.5 0.5 0.5 0.5 0.5 0.1 0.5 0.5 33,5
Objectives
We will adopt in WPB a step by step approach aiming at managing a joint trans-national calls
programme at international level. This includes an international call design, launching, selection of the
research proposal, propositions for funding (funding decisions being participating national/regional
bodies´ responsibility), as well as an international follow-up of the granted proposals.
However, planning and executing trans-national funding activities require agreements on topics and on
all implementation and administrative issues. WPB will then provide partners with a strong,
commonly agreed contractual framework as well as a joint RTD funding scheme compatible with
national/regional RTD funding bodies´ rules and administrative framework. This contractual
framework has obviously to be consistent with national legal applicable regulations.
To develop this contractual framework, we will take benefit from pre-existing processes and
documents from various running ERA-net programmes as a basis to be adapted (information gathered
in tasks A.1 and A.2). In addition we will develop specific ones (e.g. selection criteria and guidelines
for evaluators…etc).
This systematic analysis (Task A1.2) will provide WPB3 with possible solutions for overcoming the
barriers. Suggestions/schemes will be put forward in order to take advantage of previous experiences
to know how obstacles had been overcome in other trans-national activities at both national and
international level for WPB to avoid starting from scratch, saving time for an early launching of the
first joint trans-national call (JTC-1). Establishing at international level, common evaluation and
shared management systems, will be based on the best practices and procedures.
All documents necessary for the joint trans-national calls and the related procedures will be drafted
and issued in WPB.
20
Page 21
Description of work
Task B.1. Common strategy / roadmap towards a common trans-national RTD programme
with joint trans-national calls. (Task Leader: France ANR – Partner P8) - (Months 3-34).
On the basis of the outcome of the tasks A.1 and A.2, the meeting M2 (Month3) first major meeting to
enhance a common understanding (2 days meeting) will focus on the process towards a common
trans-national RTD programme on Nanomedicine for the 1st and 2nd joint trans-national calls. In the
task A.2, a Strategic Agenda for EuroNanoMed joint activities. The objective of the task B.1 is to
develop a detailed roadmap to the RTD joint trans-national call programme will be developed. This
strategic work will include:
• The development of a shared vision on current and future RTD priorities and suggested topics.
• The Synchronisation of activities and related commitment
This activity will take place at the following timeframe: For JTC-1(month 3), JTC-2 (month 13).
• Subtask B.1.1. Common strategy / roadmap to a common RTD joint trans-national

call programme. (Subtask Leader: France ANR – Partner P8) - (Months 3-34).
The roadmap will state which steps need to be taken to enable the implementation of a common RTD
joint trans-national call programme with different MSs/regions national RTD funding bodies,
mutually agreed conditions, and a coordinated virtual joint pool for funding trans-national pre-
competitive collaborative RTD proposals in Nanomedicine.
The common strategy and roadmap will be updated, before the second call, combining the input from
the possible evolution of the participating national/regional programmes, the update of the strategic
research agenda of the ETP, the input from the Executive Advisory Board, the Nanomedicine actors´
and stakeholders’ needs gained through the “workshop to gain insight priorities for JTC-2” (WS2) and
the ‘FP7 calls’ topics.
9/9/2018 draft DOW14012009 V09
• Subtask B.1.2. Design of the content of the first joint trans-national call (JTC-1).
(Subtask Leader: the Netherlands – Partner P13) - (Months 2, 6).
On the basis of the Information Exchange activities on participating RTD national/regional
programmes, (WPA – Milestone 1 - Month 2), a joint trans-national call for proposals will be designed
by the joint trans-national call EuroNanoMed consortium partners. The conclusions from the External
Advisory Board meeting (Meeting M1- Month 2-Task E3) will be considered for the selection of the
thematic fields and scope of the joint trans-national calls (common and mandatory to all
EuroNanoMed partners). An external experts panel for peer review will be selected too (Months 6)
• Subtask B.1.3. Designing the thematic contents of the second joint trans-national call
(JTC-2). (Subtask Leader: France ANR – Partner P8) - (Months 13, 18).
After the first joint trans-national call (JTC-1), considering the lessons learned (Task B.3)and the
results of the workshop to gain insight priorities as an input (task A.3- workshop WS2), the same
exercise as subtask B1.2 will take place for the subsequent second joint trans-national call (JTC-2) An
external experts panel for peer review will be selected too (Months 18)
Task B.2. Designing the contractual framework for the first joint trans-national call (JTC-1) for
proposals. (ask Leader: Spain ISCIII/FCSAI – Partner P7) - (months 3-9).
In addition to a “Memorandum of Understanding” the documents will describe the “Joint Trans-
national Call Governance” and “Joint Trans-national Call Procedures”. This task will aim in learning
from experimental practise in the course of the EuroNanoMed project; agreeing on conditions for a
common joint trans-national calls programme participation and the joint funds; designing the joint
trans-national call for proposals process, as well as the joint trans-national call and preannouncement
texts, proposals´ evaluation, funding and funded proposals´ follow-up system.
21
Page 22
• Subtask B.2.1. Preparation of the “Memorandum of Understanding” and the “Joint

Trans-national Call Governance” for the first joint trans-national call (JTC-1).
(Subtask Leader: Spain – ISCIII/FCSAI – Partner P7) - (Months 3-5).
A “Memorandum of Understanding” (MoU) and a “Joint Trans-national Call Governance” document
will be prepared and approved by the EuroNanoMed consortium. In this MoU the initial funding
contribution of each Joint Trans-national Call EuroNanoMed funding body partner, as well the central
eligibility requirements and the general scientific topic(s). The “Joint Trans-national Call Governance”
will have the provision for the “Joint Trans-national Call Steering Committee” and for modification (if
necessary) of the "Joint Trans-national Call Procedures" and other documents. It will also include as
an annex the national/regional EuroNanoMed funding body partners´ eligibility requirements.
“Procedures of the Joint Trans-national Call” are an internal document with the management details. It
can be changed if necessary with the agreement of all the Joint Trans-national Call EuroNanoMed
funding body partners. The “Procedures of the Joint Trans-national Call” will be linked to the “Joint
Trans-national Call Governance” and this will be linked to the MoU. All MoU are s expected to be
signed for the end of month 4.
• Subtask B.2.2. Preparation of the documents required for the evaluation process of
the first joint trans-national call (JTC-1). (Subtask Leader: France ANR – Partner
P8) - (Months 3-4).
Both the criteria and the procedures used for central pre-selection and selection should be compatible
with the respective common denominators of the national programmes. This would both speed up and
facilitate the central selection process, the selection of proposals by the participating national/regional
programmes and ensure that EuroNanoMed selected proposals will really be funded by the
EuroNanoMed participating RTD funding body partners. Together with written documents of peer
reviewed procedures, this subtask consists in:
- Defining the evaluation criteria to be used by external reviewers and the peer review panel,
- Suggesting the name of the members of the peer review panels to the joint trans-national call
steering committee.
The peer review panel will nominate external reviewers to review the projects.
• Subtask B.2.3. Preparation of the other documents for the first joint trans-national
call (JTC-1) process, proposal's funding and funded proposal's follow-up. (Subtask
Leader: Spain ISCIII/FCSAI – Partner P7) - (Months 3-4).
The inventory of national programmes described in WP1 ought to lead to adaptations of the
participating national/regional programmes and may already lead to significant advances in making
the different participating national/regional programmes more suitable for trans-national RTD co-
operation. The output is the other relevant documents for joint trans-national call process, proposals´
funding and funded proposals´ follow-up.
• Subtask B.2.4. Preparation of the pre-announcement text and the call text of the first
joint trans-national call (JTC-1). (Subtask Leader: Spain ISCIII/FCSAI – Partner
P7) - (Month 3-5).
A preannouncement of the first joint trans-national call (JTC-1) may be launched in advance to the
joint trans-national call text to try to early aware the potential applicants´ community. The
preannouncement text will include at least:
9/9/2018 draft DOW14012009 V09
-General aim(s) and topics of the first joint trans-national call,
-The EuroNanoMed RTD funding body partners
-General conditions for application.
-Timetable (period open for submission of proposal).
The first joint trans-national call (JTC-1) text will be published on month 5, and will include at least :
-The aim(s) and the scientific topic(s).
-The EuroNanoMed RTD funding body partners, the expected global funding available,
EuroNanoMed RTD, general eligibility requirements and if necessary the specific national /
22
Page 23
regional ones. (Funding recipients and Financial and legal modalities).

-Application issues and conditions
-Evaluation criteria. Selection criteria and procedure
-Timetable (period open for submission of proposal and date line for Final decision on
funding.)
- Granted proposals reporting requirements.
Task B.3. Feedback Analysis of the EuroNanoMed Joint Trans-national Calls. (Task Leader:
Portugal – Partner P15) - (Month 15-33)
A First Joint trans-national call (JTC-1) management implementation monitoring will be carried out.
From the first joint trans-national call (JTC-1) for proposals lessons learned will be drawn and will
help in modifying the next joint trans-national call for proposals. The experiences, from programme
managers, as well as from policy makers will be gathered and reported.
A meeting of common understanding (M6 - Month 15), will be held, both for policy makers and
programme managers. During this meeting, hurdles signalled in the execution of the first call for
proposals will be discussed. Strategies will be discussed to overcome the hurdles and to improve the
conditions for a subsequent call for proposals. Depending on the success of the first joint trans-
national call and the outcomes in term of fields, a go / no go decision will be made. If a go decision is
reached, measures will be taken to advance it tightening the links between the participating
national/regional programmes and to overcome most hurdles signalled in executing the first joint
trans-national call for proposals.
The analysis of the lesson’s learned from the second joint trans-national call (JTC-2) for proposals
will be presented during the Meeting (M9- month 33).
The knowledge gained in this task will strongly influence strategic activities and the further design of
a post-EuroNanoMed RTD programme as described in Task A.2.
Task B.4. Updating the call contractual framework for JTC-2. (Task Leader: Spain
ISCIII/FCSAI – Partner P7) - (Months 14-15).
After the first joint trans-national call (JTC-1) and taking into account the analysis of the lessons
learned from the (Task B.3). The same exercise as Task B.2. will take place for the subsequent second
joint trans-national call (JTC-2). It will be achieved through an update of:
- The design of the joint trans-national call for proposals process,
- The joint trans-national call and preannouncement texts,
- The evaluation, funding and follow-up processes.
• Subtask B.4.1. Updating the “Memorandum of Understanding” and the “Joint

Trans-national Call Governance” for the second Joint Trans-national Call (JTC-2).
(Subtask Leader: Spain - ISCIII/FCSAI – Partner P7) - (Months 14-16).
An updated version of the “Memorandum of Understanding” (MoU) and of the “Joint Trans-national
Call Governance” document will be prepared and approved by the NSC.MoU Signatures expected for
month 16.
• Subtask B.4.2. Preparation of the documents required for the evaluation process of
the second joint trans-national call (JTC-2). (Subtask Leader: France ANR –
Partner P8) - (months 14-15).
All documents required for the evaluation process of JTC-2 will be updated from the one used for
JTC-1.
• Subtask B.4.3. Updating of the other documents for the JTC-2 process, proposals´
funding and funded proposals´ follow-up. (Subtask Leader: Spain ISCIII/FCSAI –
Partner P7) - (Months 14-15).
23
9/9/2018 draft DOW14012009 V09
Page 24
Based on lessons learned and experience from JTC-1, all documents will be updated.
• Subtask B.4.4. Preparation of the pre-announcement text and the call text of the
second joint trans-national call (JTC-2). (Subtask Leader: Spain ISCIII/FCSAI –
Partner P7) - (Months 13-16).
According to the previous subtask B4.1 to B4.3, preannouncement text (month 13-14) and call text
(month 15-16) will be prepared.
Deliverables.
B1. Definition of procedures for the calls (months 4 and 15)
B2. Launch of the first Joint Trans-national Call (JTC1) (Month 6)
B3.Selection of the external experts panel for peer review (Months 6 and 18)
B4. Report on the analysis and lessons learned from the joint trans-national call results (months
15-33)
B5. Launch of the second Joint Trans-national Call (JTC2) (Month 16)
Milestones and expected results.

Milestone 3: Meeting M3 (Month 4): go/no go decision to launch the 1st joint trans-national call
(2 days meeting).
Milestone 4: Meeting M6 (month 15) : go/no go decision to launch the 2nd joint trans-national
call
24
Page 25
Work package C: Implementation of trans-national Calls for Proposals

(WPL: Veneto Nanotech – Partner P23)
Work package WP C Start date or starting event : Month 3

number
Work Package title Implementation of 2 trans-national Calls for Proposals
Activity type COORD
Innoba MOH- RANN
Participant CEA ITT
sque
CSO IS
LAS Senternovem
Participant n° 1 2 3 4 5 6 7 8 9 10 11 12 13
9/9/2018 draft DOW14012009 V09
Person-months 1.2 0.1 2 1.2 0 1.2 3.0 2.2 1,7 1.2 1.2 1.2 1.2
Participant R
FCT ANCS CNMP SRC
OVA AK
LSC VED
Nanot.
MRW
Total
Participant n° 14 15 16 17 18 19 20 21 22 23 24
Person-months 1.2 1.2 0 1.2 1.2 1.2 1.2 1.2 0.1 18, 1.2 44,3
2
Objectives
WPD will set up and execute trans-national funding programme which will be based on the commonly
accepted contractual framework commonly agreed in WPB. Through a step-by-step coordination with
two successive joint calls, the consortium will ensure the visibility of the integration process at policy
maker’s level as well as in the scientific community.
As a result of WPB, documents such as application forms /guidelines, evaluation forms / guidelines,
will be prepared in agreement with the whole consortium. This includes specificities linked to the
national regulations (specific for each partner).
EuroNanoMed aims at linking national programmes designed for stimulating and enabling co-
operation between industrial (especially SME’s), academic and, clinical/public health partners
specifically in Nanomedicine and focus on the strategic research priorities of the ETP Nanomedicine
as described in Section B1.1.2 by means of :
▪ A first call for proposals with a practical insight that will be gained in the hurdles and barriers that
arise in setting up and executing a call for proposals, the selection process as well as funding the
EuroNanoMed projects through national/regional participating programmes. The implementation
of the first joint trans-national call for proposals will be evaluated (WPB/ task B.4) and lessons
learned will be derived.
▪ The second call for proposals will be organised, possibly with a selection procedure that is more
integrated with the national selection procedures, thus speeding up the process for acquiring
national funding of selected EuroNanoMed projects. Then measures will be taken to tighten the
links between the national programmes and to overcome most hurdles signalled in executing the
first call for proposals
The lesson’s learned from the first and the second call will be used for setting up an integration report
designing the future of the EuroNanoMed beyond the 36 months.
25
Page 26
Description of work
Task C.1: Implementation of a call office (Task Leader : Veneto Nanotech – Partner P23) -
(Months 3-24) A specific helpdesk aiming at providing help for tenders will be established in the
Basque Country, providing the following support:
• Provide information on EuroNanoMed activities
• Provide checklists on IPR and contracts principles guidelines
• Provide links with the EC helpdesks (IPR, Ethics, etc), and a reference list on specialised national
offices for ethics, regulation, IPR, etc.
• Give advice on eligibility, deadline, etc, when preparing a project proposal to be submitted to
EuroNanoMed).
At national/regional level as appropriate, a local helpdesk/hotline facility will provide relevant
national information for trouble-shooting with regard to participation rules, eligibility of the projects,
ethics, IPR issues, project management, consortium agreements, etc. It will be complemented by
Telephone contact point with programme managers at national/regional level (as appropriate).
The trans-national joint call office will also support the EuroNanoMed consortium, taking in charge
the administrative tasks related to the submission of proposals, their expertise and selection and the
relation with the tenders. The main stages of the call office activities are during the matching phase of
projects up to the end of the selection of the projects. All the Executive Board, with the help of the
Network Steering Committee, and the coordinator will be committed in these call office activities.
Task C.2. Implementation of joint trans-national Call(s) for Proposals according to the
framework decided in WPB. (Task Leader: Veneto Nanotech – Partner P23)- (Months 2-14; 14-
26)
Based on the outcome of the Workshop of common understanding for the 1st Joint Common Call
9/9/2018 draft DOW14012009 V09
(Meeting M2), a first Joint Common Call for proposals is to be designed in WPB by the consortium
partners at NSC level, focused on selected application fields.
• Subtask C.2.1. Preparation of the procedures and tools for the first Joint Trans-
national Common Call for project. Task Leader : Basque region – Partner P3 (Months 2-5)
According to WPB, all the relevant documents, templates, guidelines, and on-line tools for the
implementation of the first JTC will be developed for on-line access and management.
• Subtask C.2.2. Execution of a First Joint Trans-national Common call for projects
(Task Leader: Veneto Nanotech – Partner P23)-(Months 6 -8)
A common call for proposals is published, and made available through all consortia partners. The call
for proposals is open approximately for a period of three months. The helpdesk will be available
during this phase, where potential applicants can ask any questions regarding the ‘joint call for
proposals’.
• Subtask C.2.3 Evaluation procedure. (Task Leader: Veneto Nanotech – Partner

P23)- (Months 8 -10)
Eligible proposals will be reviewed through an international peer-reviewed system under the
supervision of the call steering committee of EuroNanoMed consortium, according to the criteria
developed in WPB.
• Subtask C.2.4 Approval and funding decision at national level. (Task Leader: Veneto
Nanotech – Partner P23)-(Months 10-12)
The Network steering committee of EuroNanoMed consortium will make the final decision for
funding in relevance to the rules and procedures applying to the respective EuroNanoMed
country/regional funding partners. Within at least the funding commitments stated in the
Memorandum of Understanding, and based on a” common virtual pot” for funding (each partner funds
the part of the project carried out by the entities with legal address in its respective territories.)
26
Page 27
• Subtask C.2.5 Project execution and dissemination (Task Leader: Veneto Nanotech
– Partner P23)-(start month 13)
During the project execution of the selected projects the EuroNanoMed consortium leader will oversee
that a periodical reporting on a EuroNanoMed reporting form will be passed on from the national
funding agency to EuroNanoMed. All trans-national projects will be followed by EuroNanoMed, and
the completion of deliverables will be monitored globally by EuroNanoMed via the trans-national
project coordinator. The financial justification and control of funds granted to each project consortium
partner and administrative checks will be carried out according to funding bodies´ respective legal
frame work and procedures.
The subtasks C.2.1, C.2.2, C.2.3, C.2.4 and C.2.5 will be repeated for a subsequent second Joint
Trans-national Common Call for projects (month 14-26). After the implementation of the first
Joint Common Call, the evaluation of the results obtained and the analysis of the lessons learned, it
will be decided to implement a subsequent second call for proposals.
Task C.3: Joint Trans-national Calls announcement and communication (Task Leader:
Hungary – Partner P9) - (Months 3-8 and 15-20)
Dissemination activities at European, national a regional level will be promoted before the launching
of JTC-1. The Dissemination Plan for the promotion of the call will be based on three types of actions:
1) dissemination at national/regional level, 2) participation in European relevant events and 3) design
and elaboration of dissemination material and tools. This implies that:
1) Each partner in EuroNanoMed will be responsible to disseminate the project and the call at
national and/or regional level according to their respective rules.
2) At European level, the Consortium will select relevant events (Fairs, Conferences, etc) in order to
introduce the EuroNanoMed first Joint Trans-national Call to all interested actors, explaining in depth
details about the participation rules, beneficiaries, timeline, etc. The aim of sending some EB members
to take part and communicate in these events is to draw the attention of potential beneficiaries about
the opportunities that the EuroNanoMed joint call offers (companies, especially SME’s, academic labs
and clinicians). When appropriate, the possibility to collaborate with the ETP Nanomedicine and/or
any other relevant stakeholder in order to promote EuroNanoMed will be discussed.
3) Dissemination material (leaflets, presentations, etc) will be designed and elaborated between all the
members in order to distribute this material at national/regional level and be used in European events.
All the information regarding EuroNanoMed and its Joint Common Call will be hosted on the website.
Moreover, a partner search tool will be hosted on the website. This on-line tool will contribute to help
SME’s, academic labs and clinicians to find the right strategic trans-national partner(s).
This activity will be repeated for the subsequent second JTC-2.
Deliverables
C1 set up of the joint trans-national call office (Month 3)
9/9/2018 draft DOW14012009 V09
C3 Results of the first joint trans-national call for proposals (month 14)
C4 Results of the subsequent 2nd joint trans-national call for proposals (month 26)
FP7 Negotiation Guidance Notes – Collaborative projects, Networks of Excellence, Coordination and Support
Actions, Version 1.1, 2 March 2007
27
Page 28
Work Package D: Non-technological innovation barriers (WPL: Germany – Partner P6)
Work package WP D Start date or starting event : Month 1

number
Work Package title Non-technological innovation barriers
Activity type COORD
Innoba MOH- RANN
Participant CEA ITT
sque
CSO IS
LAS Senternovem
Participant n° 1 2 3 4 5 6 7 8 9 10 11 12 13
Person-months 0.3 0.1 0.3 0.3 0 12.4 0.3 0.3 0.3 2 0.3 0.3 4
Participant R
FCT ANCS CNMP SRC
OVA AK
LSC VED
Nanot.
MRW
Total
Participant n° 14 15 16 17 18 19 20 21 22 23 24
Person-months 0.3 2 0 0.3 0.3 0.3 0.3 0.3 0.1 2 0.3 27.1
Objectives:
In the healthcare sector, the knowledge of non-technological innovation barriers, ranging from
regulatory aspects to concerns about safety and sustainability, is important to successfully transform
results of research and development to the market.
This especially applies to new fields like Nanomedicine. At this stage, nanomedical products have
overcome the classical borders between medical products and pharmaceuticals. Typical items of
Nanomedicine - like drug eluting stents or drug carrying nanoparticles - have properties of medical
products and pharmaceuticals at the same time. However, these two classes are subjected to
different regulatory frameworks. This fact is the source of imponderables with regard to market
accreditation, as companies have difficulties to anticipate which framework will match their product.
As these imponderables in regulation may delay market exploitation substantially, but also hinder or
even impede large industrial R&D investments upfront, reviewing existing regulations with regard to
Nanomedicine and identifying possible gaps that may delay market access of innovative products is
a very significant accompanying measure, if not a prerequisite to market-oriented R&D.
Since these frameworks are set in place on a European level these questions have to be considered at
a European rather than at a national level. This issue is critical to avoid any loss of resources and
efforts for MSs, companies and research/clinical communities, and to ensure that the development of
new products could get fast market authorization to finally benefit the patient. This is also the
reason to include this work package in the ERA-Net EuroNanoMed. Supporting projects via the
calls in EuroNanoMed has no reason if imponderables in regulation will delay market access.
Hence, the objectives of WP D are:
• To identify, structure and survey non-technological innovation barriers on national- and EU-
wide level, with a special focus on regulatory affairs. This task will be carried out in close
collaboration with WP1 and the involvement of ETP Nanomedicine, EMEA, IMI and relevant
stakeholders and associations.
• To suggest options to overcome possible non-technological innovation barriers to support the
trans-national RTD projects between industries (especially SMEs), academic labs and clinicians.
• To implement a common EU-wide understanding concerning non-technological innovation
barriers to have a lasting effect for future calls and on the view of a post ERA-NET
EuroNanoMed phase for a real benefit for patients and economics.
• To review issues raised by Nanomedicine to support the specific and/or general safety aspects
to foster exploitation on the one hand and to inform relevant stakeholders involved in regulation
and reimbursement.
28
9/9/2018 draft DOW14012009 V09
Page 29
Description of work
All The EuroNanoMed partners will have a beneficial input in the WP as multiplier of the efforts
towards national exploitation-oriented stakeholders which should participate in the study. The
results obtained in WP5 should already benefit ERA-NET participants in the second call and
further on support future calls and research activities. The work package 5 will be led by partner
6 (Germany) in close cooperation with partner 13 (The Netherlands) and partner 23 (Veneto
Nanotech).
Task D.1 Mapping of Nanomedicine related Safety Issues (Task Leader: The Netherlands –
Partner P13) - (Months 6-12)
EuroNanoMed will implement in collaboration with the ELSA boards of the ETP Nanomedicine and
Nano2Life network of excellence, as well as the recent FP7 CSA project “roundtable in
Nanomedicine” (NMP programme)
• Subtask D.1.1 – Overview of Safety issues (Subtask Leader: Veneto Nanotech –

Partner P23) – (month 6-9)
An inventory of structures, advices, recommendations, position papers, projects and most relevant
questions related to general safety aspects already available at a European level, comparison with
North America and Japan.
• Subtask D.1.2 – Wrap-up of safety issues (Subtask Leader: The Netherlands –

Partner P13) – (month 9-12)
A synthetic report, summarizing the analysis, conclusions and recommendations for safety issues
within Nanomedicine will be written.
Task D.2 Expert workshop on Regulatory Affairs (WS1) (Task Leader: Germany – Partner P6)
- (Month 12)
In the first stage of the WP, non-technological innovation barriers, especially regulatory aspects for a
later industrial exploitation, will be identified on national and EU-wide level through a focussed
expert workshop. The expert group will outline the barriers that exist in the frame of national and EU
guidelines concerning Nanomedicine topics.
The identification will be done according to the topical classification of the strategic research agenda
of the ETP Nanomedicine. Regulatory aspects for one exemplary subfield of Nanomedicine will be
highlighted and discussed. Therefore, diagnostics (especially molecular imaging) has been chosen as
exemplary subfield due to its importance to both therapeutic and preventive medicine and,
accordingly, its impact on therapy costs and reimbursement. An expert meeting (planned up to 25
participants) with relevant stakeholders and exploitation- oriented ERA-NET participants as well as
the external advisory board of EuroNanoMed will be realised in Month 12.
• Expert workshop and 2 expert core group meetings on diagnostics as exemplary subfield of
Nanomedicine
• Reports and conclusions of the expert workshop as input for the ERA-Net participants by the
chairs of the workshops
Task D.3 Market-oriented Survey on Regulatory Affairs (Task Leader: Germany – Partner P6)
- (Month 12-24)
On the basis of the results of D1.1, a questionnaire concerning non-technological innovation barriers
with an emphasis on regulatory affairs will be generated. It will serve as a starting point for a
focussed survey, taking into account exploitation-oriented stakeholders experienced in regulatory
29
Page 30
affairs as well as pre-dominantly industrial participants in the calls.

In the next step, an overview concerning non-technological innovation barriers and possible options
to overcome these problems will be created. This will be done on the basis of selected case studies
concerning non-technological barriers with special focus on the topics of regulatory aspects for the
field of Nanomedicine (predominantly on diagnostics and molecular imaging). The work will be
done in close collaboration with the ETP Nanomedicine, EMEA and the other relevant institutions.
• Market-oriented survey on regulatory affairs with respect to diagnostics and molecular imaging
• Synthetic Report of the market-oriented survey and the expert workshop on regulatory affairs
9/9/2018 draft DOW14012009 V09
Deliverables
D1 Overview of the most relevant documents on Nanomedicine related Safety Issues (resulting
from subtask D.1.1) (Month 8)
D2 Synthetic report for safety issues, summarizing the analysis, conclusions and
recommendations (Month 12)
D3 Expert workshop (WS1) (Month 12)
D4 Report and conclusions of the results of the expert workshop as an input for participants in
the second call (Month 18)-the preliminary results at month 14 will be used as an input for the
meeting M6.
D5 Market-oriented survey on regulatory affairs with respect to diagnostics and molecular
imaging (Month 24)
D6 Synthetic Report of the market-oriented survey and the expert workshop on regulatory
affairs (Month 34)
Milestones and expected results

Results of the WPD will be used as an input for :
• Milestone 4 (Meeting M6) (Month 15). “Workshop of common understanding
and Go/No Go for a second joint trans-national Call”
• Milestone 5 (Meeting M9) (Month 34) : Conception and design of a post
EuroNanoMed programme frame (Milestone 5 – month 33)
30
Page 31
Work Package E: Management and support
Work package WP E Start date or starting event :

number Kick off meeting , January 2009
Work Package title Management and support
Activity type MGT
Innoba MOH- RANN Senternove
Participant CEA ITT

sque
CSO IS
LAS
m
Participant n° 1 2 3 4 5 6 7 8 9 10 11 12 13
Person-months 20 000000000000
VINN TUBIT Ven.
Participant NCBIR FCT ANCS CNMP SRC

OVA AK
LSC VED
Nanot.
MRW
Total
Participant n° 14 15 16 17 18 19 20 21 22 23 24 Total
Person-months 0 000002200 0 24
Objectives
The objective of WP E is to establish a dedicated management resource for the project, and to provide
a network of a sustainable national programme policy makers, with :
• The establishment of a practical infrastructure that will manage all of the administrative, technical,
communication and economic aspects of the consortium
• Support the respective WPL and TL in the collection of data, due to the elaboration of the progress
reports and deliverables
• Dedicate the appropriate secretariat resources needed for the organisation of the workshops and
partnering events
9/9/2018 draft DOW14012009 V09
• The regular maintenance and update of the information disseminated through the website
• Organisation, within relevant events, some presentation of the project, the contractors and partners
• Diffuse the main results and lessons learned via the website and in all relevant audiences.
• The establishment of External Advisory Board in order to ensure the contribution of other
stakeholders while designing the content of trans-national calls.
Description of work
Task E.1 Management of the co-ordination (Task Leader: France – Partner P1) - (Months 1-36)
The management of the consortium will be held by The CEA (Partner P1)
Additional personnel will be recruited to the co-ordination team to ensure that EuroNanoMed has its
own dedicated co-ordinator and a joint secretariat support staff.
The consortium management will include network administration, and the implementation of a website
available for the programme managers and policy makers :
Network administration
▪ 'secretariat' support for day to day management of the consortium
▪ management of the co-ordination structure including activities support, the knowledge
management activities and monitoring of the quality,
▪ legal and financial aspects and reporting to the commission
▪ kick off meeting, workshops and partnering events support
Internal website support for :
▪ linking all people involved in EuroNanoMed
▪ team and group meetings, progress reports and collaborative dialogue at all levels
Annual reports the annual Network Steering Committee, technical and financial reporting to the
Commission (cost statements, audit certificates, Periodic project reports) will be co-signed by the
Coordinator and the NSC Chairman.
31
Page 32
Task E.2 Set up and run of infrastructures for joint activities´ support (Task Leader: Lithuania
– Partner P21) (Months 1-4)
An electronic support system will be developed by the coordinator for the project management
activities. An EuroNanoMed website could be divided roughly into two parts, a public one (Extranet)
and an internal one (Intranet):
Public website :
▪ For publication of the information submitted to the calls and for e-submission
▪ For workshop and events calendar and announcements, help desks, call for proposals, results of the
calls, etc.
▪ Information on EuroNanoMed reports and events linked to the EuroNanoMed contribution to
ethics, safety and health economics debates (result of WPE).
Internal website, "password protected", for the Executive Board (EB) and the NSC
▪ Virtual workshop for the co-ordination activities (continuous work after meeting)
▪ Virtual workshops related to the joint Call for Proposals, aiming at the definition of an agreement
on scientific & technological objectives / thematic focus and implementation modalities (legal and
contractual framework, IPR issues, evaluation criteria, guidelines/manuals for tenders and
evaluators, financial modalities, time frame, participation rules, ...)
▪ One specific part dedicated to each Work Package Leader and Task Leader co-ordination activities
not directly implied here above: programme & policy information, best practices, workshop,
partnering events, benchmarking analysis, lessons learned and evaluation of EuroNanoMed.
The outside communication is mainly the responsibility of the coordinator under the supervision of the
operating group with the name of the relevant contact points in the partnering institutions. The Public
website will greatly contribute to support the dissemination of the information and results gained in the
different Work packages targeting:
▪ The EC, European governments and agencies,
▪ The European Nanomedicine companies, academic institutions or hospitals, associations…
Task E.3 Design and establish an External Advisory Board (EAB) (Subtask Leader: Turkey -
Tubitak – Partner P20 ) (Month 1-2)
The External Advisory Board (EAB) will be nominated at the very beginning of the ERA-net. Its
mission will be to advise when defining the topics of the EuroNanoMed calls. This board should meet
at least before the design of each call and participate and/or assist to some of the workshops. The EAB
should be composed of two scientists from academia, two industrials and two clinical/public health
experts. The members will be then selected with respect to their scientific excellence and experience in
the field. One of the industrial could be member of the European Technology Platform in
Nanomedicine. This External Advisory Board will meet independently during the meeting M1 and
during the workshop WS2.
9/9/2018 draft DOW14012009 V09
Deliverables
E1 Establishment of the Executive Board (EB) (Month 1)
E2 Establishment of a Joint Trans-national Call Secretariat (JTCS) (Month 1)
E3 Establishment of a Network Steering Committee (NSC) (Month 2)
E4 Website (Month 4)
E5 Establishment of the EAB – Month 2
Progress of EuroNanoMed will be reported to the Commission for the contractually fixed reporting
period in the form of progress reports put together by the co-ordinator. The following progress reports
are due :
E6 Periodic project reports (Months 18-36)
E7 Progress/activity report and financial report (Months 18)
E8 Publishable final report (Month 36)
32
Page 33
List and output of EuroNanoMed meetings and workshops

Name Date Main expected output WP audience
involved
Kick off meeting 15-16 January • Objectives all EB + NSC
2009 • Management rules
• External advisory board process
• Information exchange questionnaire to be finalized Terms of
reference for the website
• NSC chairman, Call committee, board chairman, WP leaders
M1: EAB meeting End Month 2 • Analysis of Nanomedicine actors expectations (clinicians, E EAB
companies, academics)
• Suggestions for the first call: topics, mechanisms and procedures, ..
M2: meeting to End month 3 • Results of the Information exchange on national programme : A, B, E EB
enhance common 2 days funding rules (Task A1)
understanding of • Strategic agenda
strategic activities • Results of the EAB meeting
• Structure of the call :Evaluation, selection processes and funded
project follow up
• MoU, call governance, call committee
• Thematic fields and scope of the JTC
M3: meeting and Month 4 • Finalisation of call content and call text B, C, E EB +NSC
go/no go for the first 1,5 (EB)+ 0,5 • Finalisation of document for call implementation (evaluation and
joint trans national day (NSC) funding)
call JTC-1 • Call communication
1st JOINT TRANS NATIONAL CALL

M 4: Evaluation Month 9-10 • Review of eligible projects through an international peer-reviewed C, E NSC (call
process (2 days system committee)
meeting) • Ranking of the proposals
M 5: Final Month 10 • Final selection C, E NSC

decision
WS 1: expert Month 12 Diagnostics : regulatory affairs D Experts +
workshop : EAB
regulatory affairs
WS 2: Expert Month 13 • Definition of thematic fields for the 2d call A, B, E Experts
workshop : +EAB
Definition of
thematic fields
M 6: meeting and Month 15 • Analysis of lessons learned from the 1st call A, B, D EB + NSC +
go/no go for the 1,5 (EB)+ 0,5 • Results of the WS 1 EAB
second joint trans day (NSC) • Results of WS2
national call JTC-2 • Structure of the 2d call : content and call text
• Result of expert meeting for regulatory affair
2nd JOINT TRANS NATIONAL CALL

M 7: Evaluation Month 21 • Review of eligible projects through an international peer-reviewed C, E NSC (call
process (2 days system committee)
meeting) • Ranking of the proposals
M 8: Funding Month 22 Final selection C, E NSC (call

decision committee)
M 9: post • Analysis of lessons learned from the 2nd call All EB+NSC
EuroNanoMed Month 33 EuroNanoMed : future programme
programme
9/9/2018 draft DOW14012009 V09
33
Page 34
B 1.3.6 Efforts for the full duration of the project:
Project Effort Form 1: Indicative effort per beneficiary per WP

Work package leaders are indicated in bold and underlined characters.
Beneficiary WPA WPB WPC WPD WPE Total person

n°/ Short name
Months per
beneficiary
1 CEA 0,1 0,5 1,2 0,3 20 22,1

2 ITT 0,1 0,1 0,1 0,1 0 0,4
3 INNOBASQUE 0,1 1,5 2 0,3 0 3,9
4 SNF 0,1 0,5 1,2 0,3 0 2,1

5 BMBF 0 0 0 0 0 0
6 VDI 0,1 0,5 1,2 12,4 0 14,2
7 ISCIII 0,1 15,2 3 0,3 0 18,6
8 ANR 0,1 5,1 1,2 0,3 0 6,7
9 NKTH 0,1 0,5 1,7 0,3 0 2,6
10 MOH- CSO 0,1 0,5 1,2 2 0 3,8
11 RANNIS 3 0,5 1,2 0,3 0 5
12 LAS 0,1 0,5 1,2 0,3 0 2,1
13 Senternovem 0,1 1 1,2 4 0 6,3
14 NCBIR 4 0,5 1,2 0,3 0 6
15 FCT 0,1 3 1,2 2 0 6,3
16 ANCS 0 0 0 0 0 0
17 CNMP 6,3 0,5 1,2 0,3 0 8,3
18 SRC 1,2 0,5 1,2 0,3 0 3,2
19 VINNOVA 0,1 0,5 1,2 0,3 0 2,1
20 TUBITAK 0,1 0,5 1,2 0,3 2 4,1
21 LSC 0,1 0,5 1,2 0,3 2 4,1
22 VED 0,1 0,1 0,1 0,1 0 0,4
23 Veneto 0,1 0,5 18,2 2 0 20,8
Nanotech
24 MRW 0,1 0,5 1,2 0,3 0 2,1
TOTAL 16,30 33,50 44,30 27,10 24,00 145,20
34
Page 35
Project effort Form2 : indicative efforts per activity type per beneficiary
Beneficiaries
Inno MOH- Senter VINNO TUBI

Activity type CEA ITT SNF BMBF VDI ISCIII ANR NKTH RANNIS LAS NCBIR FCT ANCS CNMP SRC LSC VED
basque CSO novem VA TAK
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
9/9/2018 draft DOW14012009 V09
COORDINATION/
SUPPORT
WPA 0,1 0,1 0,1 0,1 0 0,1 0,1 0,1 0,1 0,1 3 0,1 0,1 4 0,1 0 6,3 1,2 0,1 0,1 0,1 0,1 0,1 0,1 16,3
WPB 0,5 0,1 1,5 0,5 0 0,5 15,2 5,1 0,5 0,5 0,5 0,5 1 0,5 3 0 0,5 0,5 0,5 0,5 0,5 0,1 0,5 0,5 33,5
WPC 1,2 0,1 2 1,2 0 1,2 3 1,2 1,7 1,2 1,2 1,2 1,2 1,2 1,2 0 1,2 1,2 1,2 1,2 1,2 0,1 18,2 1,2 44,3
WPD 0,3 0,1 0,3 0,3 0 12,4 0,3 0,3 0,3 2 0,3 0,3 4 0,3 2 0 0,3 0,3 0,3 0,3 0,3 0,1 2
WPE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0
TOTAL 2,1 0,4 3,9 2,1 0,0 14,2 18,6 6,7 2,6 3,8 5,0 2,1 6,3 6,0 6,3 0,0 8,3 3,2 2,1 4,1 4,1 0,4 20,8 2,1 125,2
MANAGEMENT
WPE 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TOTAL 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
TOTAL
BENEFICIARIES 22,1 0,4 3,9 2,1 0,0 14,2 18,6 6,7 2,6 3,8 5,0 2,1 6,3 6,0 6,3 0,0 8,3 3,2 2,1 4,1 4,1 0,4 20,8 2,1 145,2
35
Page 36
B 1.3.7 List of milestones and planning of reviews:
List and schedule of Milestones
Milest Milestone Work Lead Delivery date Comments

one name packages beneficiary (month)
N° involved
Kick off
1 A, B, C, D, P1, P20, Month 1 Shared common understanding on
meeting
E EuroNanoMed programme and rules
P21
Meeting
2 A, B P7, P8, Month 3 common understanding of the partnering
M2
P13, programme rules and practices, leading to the
elaboration of a common strategic agenda /
road map of EuroNanoMed activities
3 Meeting B, C P23, P7, Month 4 go/no go decision to launch the 1st joint
M3 P8, P13 trans-national call
Meeting
4 A, B, C P23, P7, Month 15 go/no go decision to launch the 2nd joint
M6
P15, trans-national call
Meeting
5 A, B, C, P6, P13, Month 33 conception and design of a post
M9
D, E P18 EuroNanoMed programme frame
Project Reviews
Two Projects Reviews are planned respectively:

• During the meeting M6 after the first call, to analyse the lessons learned from the first call
before launching the second one.
• During the M9 meeting to analyse the lessons learned from the 2 calls and to design a possible
post EuroNanoMed programme.
9/9/2018 draft DOW14012009 V09
Tentative schedule of project reviews
Review Tentative timing, i.e. after planned venue Comments , if any

no. month X = end of a reporting period of review
1 After project month: 15 Venue of First review after the 1st joint trans-
Meeting M6 national call
2 After project month: 33 Venue of Second review after the 2nd joint
Meeting M9 trans-national call
36
Page 37
B2. IMPLEMENTATION
B 2.1 MANAGEMENT STRUCTURE AND PROCEDURES
At national level the organisation of RTD supportive programmes is most generally organised at two
levels with two players:
• A strategic level, the policy makers level, often beard by one ministry (e.g. Germany, Austria,
The Netherlands …etc), where the implementation, the content and the programmes funding
decisions are made (“programme Owner”),
• An “operational” level, mostly found in specific agencies (programme Manager”) in charge of
the organisation, the promotion and the implementation of the calls for proposals (selection,
funding, contracts, follow-up of the projects..).
Even if in some countries the same institution (ANR in France, NCBIR in Poland … etc) is gathering
both these two roles, the internal organisation of the ERA-Net wishes to clearly separate these two
levels.
There is a need to co-ordinate at the same time the policy makers and the agencies levels to ensure
that all partners are doing at the same time, the same tasks altogether to implement progressively the
opening of national programmes to support trans-national RTD partnerships between academic, and
companies or clinicians in Nanomedicine. This function is devoted to the two main bodies governing
the management of the EuroNanoMed initiative: The Network Steering Committee (NSC) and the
Executive Board (EB). The Major and strategic decisions concerning the Initiative shall be taken in the
frame of the NSC and operational decisions are made in the frame of the EB (ref. Consortium
Agreement – article III).
B 2.1.1 Organisation and structure of the management framework
Given the long-term nature of the proposed co-operation and to ensure the continuity of operations, a
coherent management framework as illustrated above will be established. In particular, considering the
high number of partners and taking benefit from the experience of previous ERA-Nets, the
organisation and management structure aim at having a workable and manageable consortium.
An overview of the project management structure is summarized in the scheme below.
37
9/9/2018 draft DOW14012009 V09
Page 38
Commission
NETWORK STEERING COMMITTEE
(NSC)
Joint Secretariat
Overall strategy and policy (JS)
EXECUTIVE BOARD OPERATING GROUP (OP)

•Actions Follow up + monitoring
(EB)
• Board and NSC preparation
Operational decisions
EXTERNAL ADVISORY BOARD (EAB)

Advise on call topics and area
Work package leaders (WPL) and Task leaders (TL) …

WPL A WPL B WPL C WPL D
TL A.1 TL B.1 TL C.1 TL D.1
TLA.2 TL B.2 TL C.2 TL D.2
TLA.3 TLB..3 TL C.3 TL D.3

… … … …
a. Network Steering Committee: Management of the Coordination at policy maker level
The Network Steering Committee (NSC) is the highest responsible body of EuroNanoMed and has
the overall responsibility for taking all the strategic decisions linked to the Initiative, monitoring the
progress made towards the achievement of the global goals of the initiative and providing the EB with
general strategic orientations.. It will decide on all major and strategic issues addressed during the
course of the project, which will substantially affect the scope, direction and content of the project.
The NSC is composed of one senior director level representative for each programme owner involved
in the EuroNanoMed Initiative. NSC members may be represented by a substitute at anytime. NSC
tasks are:
o To decide on critical issues e.g., the launch of the calls, the maximum national funding
available within the frame dedicated to each calls for each country,
o To make decisions regarding any other strategic issue, including the case of a partner
raising exceptional difficulties.
The NSC will directly take part to the trans-national strategic activities, workshops, and the evaluation
of EuroNanoMed programmes, by networking and attending regular meetings, in close collaboration
with the EB.
The NSC will be chaired by a rotating Consortium Leader (CL), elected for a period of one year (ref.
"Consortium Agreement" art III). The NSC will regularly meet, at least once a year and when
necessary on a case-by-case decision. During the meetings, the NSC chairman is assisted by the
representative from the hosting country as vice-chair, if not elected as a chair.
38
Page 39
b. Executive Board: Management of the coordination at “operational” level
The body responsible of the execution of the project is the Executive Board (EB). Its role consists in
(i) implementing the work necessary to achieve the objectives of the Initiative, (ii) reporting to the
NSC and (iii) making to the NSC any appropriate proposals relevant to the strategy.
The EB is composed of representative of “programme managers” institutions, in charge of the
9/9/2018 draft DOW14012009 V09
operational management of Nanomedicine RTD funding programmes, some of them being the work
package leaders or the task leaders and the co-ordinator who chairs the EB. Thus, considering the
compatibility with the rules applicable to their national programmes, they are the key persons for
defining the guidelines and procedures applicable to the EuroNanoMed common joint calls for
proposals (e.g. eligibility, international common selection process and criteria, funding process,
guidelines for applicants, for experts, etc…).
For each work package (WP) a Work package Leader (WPL) has been appointed by the NSC. The
WPL is responsible for the co-ordination, planning, monitoring and reporting of the respective WP
activities (including contributions to progress reports) as well as the coherence of this WP with other
WPs in the network. He will be assisted by a set of Task Leaders (TL) who will co-ordinate the
respective tasks (T) of the WP on the scene and are responsible for furnishing the deliverables of the
single tasks and providing the WPL with the required reports and progress statements. TL may meet
under the chairmanship of the WPL, if this is deemed necessary.
On a regular basis, the Executing Board (EB) being chaired by the CO and consisting of the WPLs and
programme managers partnering in the initiative will meet to analyse the results and the progress
made, prepare the actions to be implemented and - if necessary - suggest remedial actions to the NSC.
During the meetings, the EB chairman is assisted by the representative from the hosting country as
vice-chair. The EB works with the help of a secretariat, and EB decision reports are submitted for
validation to the NSC.
The Co-ordinator (CO) will be supported by a Joint Secretariat (JS), which will be established at the
co-ordinator location and will consist of one additional scientist and a secretary support. The tasks of
the JS include all aspects of the administrative support of the co-ordinator and the other management
bodies as well as all the entire communication and interaction with the European Commission.
A small and reactive Operating Group (OG) will assist, and advise the coordinator, suggesting
appropriate solutions to any emerging questions, during the preparation of the EB and NSC meetings
and the implementation and follow up of the EB and NSC decisions. OG meets as often as required, at
least every two months. The Operating Group consists of the coordinator, the Work package leaders
and the Consortium Leader (NSC Chairman).
After project starts the EB will nominate an External Advisory Board (EAB) consisting of high-level
experts from partner countries (2 academics, 2 from industry and 2 from clinical/hospital setting), as
described in WPE, subtask E.3. The EAB will be involved in the strategic activities and priorities in
order to help in delineating topics for the EuroNanoMed joint trans-national calls.
The management of the co-ordination (WPE) will include a day to day follow up of the activities: (i)
the monitoring of the common understanding quality, (ii) the legal and financial aspects, (iii) the
overseeing of gender equality, societal matter and programme sustainability, and (iv) the reporting to
the Commission.
A dedicated website will ensure a distinct and relevant identity of EuroNanoMed, plus an internal
password protected area for all the participants, enabling the possibility of virtual networking
(electronic communication platform). A webmaster will be subcontracted for the establishment of
this website. Modern electronic communication systems as well as project management software
systems will be used in all project management tasks.
39
Page 40
c. Coordination between NSC and EB
It is essential to have an efficient link between the strategic and the operational level. This is achieved
through:
• The NSC chairperson is responsible of the “top-down” link: systematically attending the EB
meetings, he reports to NSC on possible difficulties raised at EB and already he could ensure that
EB is following the strategy defined by the NSC.
• The Coordinator ensures the “bottom-up” link: among other tasks, the co-coordinator should
implement the EB and NSC decisions. Chairing the EB, he is at the same time attending the NSC
meetings.
• Moreover the Operating Group, (Co-ordinator, the NSC Chairperson and the five WP leaders) is
advising the Coordinator in the overall management of the consortium, and specifically, in the
implementation and the follow up of the EB and NSC decisions and in the preparation of the EB
and NSC meetings.
NETWORK STEERING COMMITTEE
(NSC) Policy makers

Programme owners : level
Overall strategy and policy
9/9/2018 draft DOW14012009 V09
• EuroNanoMed decision processes and procedures
• The NSC Chairman : Member of EB
• The Co-ordinator : chair of EB and member of NSC
• the Operating Group
EXECUTIVE BOARD Operational level
(EB)
Programme Managers :
Operational decisions
B.2.1.2 Internal Reporting, Decision Making Structures, Conflict, Management,

Moderation
The network's management and controlling strategy makes use of a standardised reporting system and
commonly agreed decision making processes that will become an integral part of a consortium
agreement which will be signed after the contract with the EC (ref. Consortium Agreement).
Every 6 months, and after consultation with their Task Leaders, the Work package leaders have to
provide the Co-ordinator with a progress report (PR), which will enclose a ”cost- and time-to-
complete statement” for all tasks in progress.
A standard form for this internal reporting system will be prepared by the CO before project starts.
The chairperson of each Consortium Body or working Group shall produce written Minutes of each
meeting which shall be the formal record of all decisions taken. He shall send the draft to all of its
members within 10 calendar days of the meeting. The Minutes shall be considered as accepted if,
40
Page 41
within 14 calendar days from sending, no member has objected in writing to the chairperson with
respect to the accuracy of the draft of the Minutes.
Annually, the CO will submit to the NSC an annual report (AR) including all relevant management
and financial information (e.g. distribution of the financial contribution received between the partners)
and - on demand of the NSC – report on any other specific issue. Beyond the information of the last
year, a management working plan (MP) for the next year (including a new reporting and meeting
schedule) has to be presented to the NSC, which will become a binding amendment to the consortium
agreement after its approval by the NSC. In the regular annual meeting of the NSC, the above
mentioned documents will be discussed and adopted. Hereafter, the CO is entitled to use them for the
reports to the European Commission at the end of each reporting period.
According to the Consortium Agreement:

• The NSC decisions related to financial and administrative matters concerning the joint trans-
national call will be taken on the basis of one vote per participating funding body. All other votes
in the NSC will be taken on the basis of one vote per country, meaning that if more than one
national and/or regional partner from the same country participate in the vote, their cumulative
vote is counted as one.
• All votes in the EB will be taken on the basis of one vote per Programme Manager.
• A decision in the NSC/EB will be assumed to be taken if more than 50% of the total number of
votes is in favour of this decision. This total number of votes will be determined counting only the
votes in favour and against the motion, i.e. abstention votes being not considered.
• All disputes arising out of or in connection with the Consortium Agreement contract shall be
finally settled under the Rules of Arbitration of the International Chamber of Commerce in
Brussels by one or more arbitrators appointed in accordance with the said Rules. The award of the
arbitration shall be final and binding upon the Parties concerned. The language of arbitration shall
be English. Parties shall bear the costs for arbitration as decided in the arbitration award.
B 2.2 Beneficiaries
• P1 :France - Atomic Energy Commission (CEA)
CEA is a public research body (French EPIC statute) which conducts strategic multi-year research and
innovation programmes of national importance. These cover nuclear and non-nuclear energy, defence,
medicine, nanosciences, micro-electronics, software and environmental protection and remediation.
Civilian activities are conducted under the auspices of the Ministry of Higher Education and Research
(Ministère de l'Enseignement Supérieur et de la Recherche) and of the Ministry of Ecology and
9/9/2018 draft DOW14012009 V09
Sustainable Development (Ministère de l’Ecologie, du Développement et de l’Aménagement
durables). CEA staff devoted to civilian activities amounts to 10,800 research staff. Current annual
budget amounts to €2 billion, of which less than 45 % come from government subsidies. CEA is a
major actor in transfer from research to industry, supporting the creation of 100 spin-offs over the last
twenty years, three of them being of world class in their domain of activity (ST-Microelectronics,
SOITEC, SOFRADIR).
Over the last decade, CEA has been largely involved in EC and EURATOM research Framework
Programmes. Under FP 6, it took part in 350 projects (54 as coordinator) and in 3 ERA-nets
(ASPERA, HY-CO, and NANOSCI-ERA).
The CEA is the co-owner of the “C’Nano IdF” regional programme in Ile de France (Paris region).
Created in 2005, this programme aims at supporting RTD nano sciences and nanotechnology projects,
including Nanomedicine, through specific calls for projects and dedicated grants (10.9 M€ in 2006, 9.9
M€ in 2007).
41
Page 42
The CEA will be responsible of the coordination of the EuroNanoMed initiative. As the coordinator,
its responsibility will be to lead the Work Package E and to implement the task “E1 Management of
the coordination”.
At CEA the staff will involve:

• A senior Programme Manager: Dr. Pierre-Noël LIRSAC, born in 1962 got a PhD in biotechnology
and started as researcher in radiation biology and joined in 1990 the CEA as Head of laboratory at
the life Science Directorate. From 1996 to 2002 and after a nine months period dedicated to
prepare a study on vaccines for the European commission, he has been nominated as the head of
the Radiation protection, Biology and Medicine department of the National Institute for Sciences
and Nuclear Technologies.
Early 2002 he joined the Directorate for Enterprises of the French Ministry of Industry as Head of
the Biotech and Health Department. The duty was to elaborate the national policies, programmes
and action plan to support the attractiveness and competitiveness of the French environment for
the French bio industry including innovation, R&D, regulatory, economic and fiscal aspects.
Secretary of the French “Strategic Council for Health Industries” chaired by the Prime Minister
from 2004 to end 2006, he initiated and founded the EUROTRANSBIO ERA-NET initiative and
chaired its network steering committee during the first 2 years. Since End of 2006, he is Deputy
Director of the Technology for health programme at CEA.
• A young project manager, Virginie SIVAN. After a PhD in biology, she spent 2 years in
pharmaceutical industry as a scientist, and worked for 3 years in the field of biotechnology and
health as project manager. She was responsible during these 3 years of the management and
coordination of national scientific networks (ECRIN programmes) aiming at supporting
collaborations and partnerships between academic laboratories and companies. During this period
she also had to manage a national call for proposals including the scientific follow up of the
funded projects. In collaboration with Dr. Lirsac she will contribute to all coordination and
management tasks and actions.
• P2 : Basque Region – Ministry of industry, commerce and tourism (ITT)
The Department of Industry, Commerce and Tourism (ITT) is the present coordinator of the Basque
R&D Policy. That policy is widely known throughout the whole Europe as an example of a very
strong regional compromise with technology and industrial development.
The new government, elected in Spring 2005, is committed towards the Lisbon Objective of 3% GDP
by 2010, and has significantly increased the R&D budget up to 82 Million € for 2005. The political
programme reflects the need for the INTERNATIONALISATION of research. R&D is organised in
the PCTI 2010 (Science, Technology and Innovation Plan), with key strategic areas of focus.
Furthermore, Innobasque -Basque Innovation Agency- participates in the European strategy of the
Basque Government. The Internationalisation Area of Innobasque has high level project management
skills and international background in charge of the development of this strategy. In this respect, ERA-
NET is an instrument that fits the overall Basque long term research strategy.
The Basque Region has extensive experience in the coordination and management of ERA-NET
projects, coordinating MANUNET ERA-NET, with the Government itself as the President of the
Steering Committee and INNOBASQUE as the acting coordinator, absorbing all contract management
and administrative tasks; and participating in COMPERA and HY-CO as a full partner. Innobasque
participates in INNONET projects such as INNET. In liaison with the Department of Industry,
Tourism and Trade of the Basque Government, it also participates in MNT-ERA-NET (management
group), EUROTRANS-BIO. In liaison with the Department of Environment also participates in
9/9/2018 draft DOW14012009 V09
42
Page 43
SUSPRISE ERA-NET. Recently it is also involved in the two new ERA-NETs: SMARTGRIDS
(Smart Electricity Networks) and ERNEST (Sustainable Tourism).
• P3 : Basque region - Innobasque
The Basque Innovation Agency – Innobasque - is the new agency launched from the presidency of the
Basque Government in order to merge different entities that existed before. It is a not-for-profit
association set up to coordinate and promote innovation in all fields in the Basque Autonomous
Community, and to foster the entrepreneurial spirit and creativity.
Innobasque is made up of the agents of the Basque Science, Technology and Innovation Network,
private companies, public Basque institutions, official representatives of Basque management and
workers and all kinds of organisations connected with innovation. Its operational model is based on
activities that promote the values and attitudes associated with innovation in Basque society, on
actions that spread the image of an innovative Basque Autonomous Community to the outside world
as an advanced centre for RDI, as well as on activities that generate the dynamics for innovation in
Basque companies and organisations.
The Internationalisation Area or department of Innobasque is in charge of the internationalisation

strategy of the R&D programmes for the Basque Government.
It complements the functions of the Association for the Promotion of Industry (SPRI) and the
Government itself, by executing the functions of:
- Evaluation: Instrument for the evaluation and monitoring of research projects for the Basque
Government and in particular those aspects related to international projects. Evaluation criteria are
increasingly demanding presence in international programmes as a means to demonstrate
excellence with external indicators.
- Programme planning: In charge of proposing regulation compatibility and convergence with
European guidelines as well as looking for areas of specialization that will complement those
covered by the European Community.
- Programme internationalisation: Acting as a project office to analyse, benchmark, capture
opportunities for improvement, organize workshops and involve government officials in mid- and
long-term programme decisions.
Innobasque has extensive experience in the coordination and management of ERA-NET projects,
coordinating MANUNET ERA-NET, and participating in COMPERA and HY-CO as a full partner.
Innobasque participates in INNONET projects such as INNET. In liaison with the Department of
Industry, Tourism and Trade of the Basque Government, it also participates in MNT-ERA-NET
(management group), EUROTRANS-BIO. In liaison with the Department of Environment also
participates in SUSPRISE ERA-NET. Recently it is also involved in the two new ERA-NETs:
SMARTGRIDS (Smart Electricity Networks) and ERNEST (Sustainable Tourism).
In EuroNanoMed, Innobasque will be in charge of the task C2.1.
Juan Tomas Hernani : General Manager of Internationalisation Area. More than 17 years of
experience in general business management. Since 2004, General Manager at Basque Agency for
International R&D Development, Eurobulegoa, recently absorbed by Innobasque – Innovation Basque
Agency. Long experience as Board Member in a number of IT, food, fashion and design and
biotechnology companies and property developers. General manager at the Isabel-Garavilla group, and
founder CEO of KEON-AZERTIA. Previously Technical Manager at Robotiker. He also worked at
Hewlett Packard and for the Basque Energy Board, EVE. Mr Hernani is qualified as an Industrial
Engineer at the Higher School of Industrial Engineering and Telecommunications in Bilbao
(UPV/EHU) and BA in Business Science and MSc from Cranfield Institute of Technology.
43
Page 44
Nerea Blázquez Legarreta : Responsible of the following tasks in the Internationalisation Area in
Innobasque: Management of the Observatory for the Basque participation in RDi projects of EU;
leadership of the Spanish Network PYMERA for the promotion of the Spanish PME participation in
RDi European projects; assistance in the coordination and management of 21 Basque Contact Points
(working groups corresponding to each area of 7FP); consulting for the promotion of the participation
9/9/2018 draft DOW14012009 V09
of Basque entities, specially PME, in European projects; management of the Basque participation in
the following ERA-NET projects: REPARTIR-PLUS, COMP-ERA, HY-CO, EUROTRASN-BIO;
organization of workshops and conferences related to 7FP. Previously, trainee in the Delegation of the
Basque Country in Brussels, covering the areas of enterprise, trade, energy, research and development,
external relations, public health and consumers and public procurement. Ms Blázquez has a Degree in
Business Administration and Management and a MBA in the Faculty of Economic Sciences, La
Comercial, University of Deusto; as well as a Master in “European Studies: European Policies and
institutions, in the Institut d´études européennes” of the Catholic University of Louvain-La-Neuve
(UCL).
• P4: Switzerland - Swiss National Fund (SNF)
The Swiss National Science Foundation (SNSF) is Switzerland’s leading provider of scientific
research funding. The SNSF annually supports some 7,000 researchers, 5,500 or more of whom are
aged 35 years or younger. With its federal mandate, it supports basic research in all disciplines, from
philosophy and biology to the nanosciences and medicine. It also invests in applied research in various
scientific fields.The focus of its activities is the scientific endorsement of projects submitted by
researchers. The best applicants are funded by the SNSF with an annual total amount equalling
approximately CHF 500 million.
Established in 1952 as a foundation under private law, the SNSF has the autonomy it needs to promote
independent scientific research. The SNSF is committed to promoting young scientists and works to
ensure that scientific research in Switzerland has the most favourable conditions for developing
internationally. It also encourages dialogue between scientists and representatives in society, politics
and the economy.
The Swiss National Science Foundation (SNSF) is a central instrument for state-funded research and is
based on the principle of scientific self-governance. Its activities focus primarily on funding
investigator-driven research and promoting junior scientists for which it offers a broad palette of
programmes. The SNSF attaches great importance to funding interdisciplinary research projects and
supporting equal opportunities for women and men. The standards for equality are anchored in
existing guidelines. In addition to national funding programmes, the SNSF is also committed to
initiatives on an international level aimed at reinforcing the pre-eminence of Switzerland as a research
location. The guidelines for medium- and long-term funding policy are in the so-called multi-annual
programmes. In addition, the SNSF provides expert opinions on current scientific and research policy
issues.
The Swiss National Science Foundation (SNSF) provides a wide range of funding programmes most
of which are clearly for research projects . It also supports innovative ideas in new areas through
funding for “free” or open-ended research. The SNSF also supports junior researchers through
bursaries and fellowships (individual fellowships and grants). Junior researchers can apply for
financial support through these funding programmes for anything from producing their dissertations to
sponsorships for an assistant professorship. The SNSF also supports applied research through the
national research programme which aims to solve current problems facing Switzerland. As such, it
focuses on areas underpinning existing research structures and that reinforce the position of the
country in strategically important areas such as nanosciences or climate research. In addition, the
SNSF supports several joint programmes designed to reinforce international collaboration with key
partner countries.
44
Page 45
With the aim of developing synergies with ongoing national programmes touching this field, and of
strengthening our funding efforts for independent project submissions, the Swiss National Science
Foundation has decided to participate in the ERA-Net Nanomedicine. Related National programmes
are “Nanoscale Science”, “Opportunities and Risks of Nanomaterials”.
The contact persons are. Dr. Aysim Yilmaz, Head of the Division of Biology and Medicine, and Dr.
Beat Butz, Head of the Division of Targeted Research.
• P5 : Germany -Federal Ministry of Education and Research (BMBF)
The Federal Ministry of Education and Research in Germany (BMBF) is the ministry primarily
responsible for defining and executing the German federal government’s educational and research
policy. The BMBF performs a number of different tasks within the scope of its constitutional
responsibility:
• regulation of non-school vocational education and training and continuing education and the
necessary policy and coordination tasks,
• Support for Research,
• Legislation governing training assistance and its financing (together with the federal states),
• Talent promotion, support for young researchers and
• Promotion of the international exchange of trainees, students, participants in continuing
9/9/2018 draft DOW14012009 V09
education programmes, instructors, academics and scientists
By means of special funding programmes, which are based on public competitive calls and peer-
review evaluations, the Federal Ministry of Education supports innovative projects in various research
sectors; e.g. in basic sciences, sustainable development, information and communications
technologies, life sciences, chemistry and materials science, transport or space research.
The Federal Ministry of Education and Research has been directed by Federal Minister Dr. Annette
Schavan since November 2005. The Ministry has around 750 staff members at its main office in Bonn
and around 250 at its Berlin office. The Federal Ministry of Education and Research is the owner of
the national funding programme “WING - Werkstoffinnovationen für Industrie und Gesellschaft”,
which will be the German national programme participating in the joint calls of the proposed ERA-
NET on Nanomedicine. (http://www.bmbf.de/de/3780.php)
Dr. Petra Wolff is a scientific officer at the Division of “Nanomaterials, New Materials” of the BMBF.
She is the programme officer responsible for the Nanomedicine section of the WING-Programme. Dr.
Wolff holds a PhD in Biology from the University of Düsseldorf. She will be the representative of the
BMBF in the Network Steering Committee of the ERA-Net Nanomedicine.
• P6 : Germany - VDI Technologiezentrum GmbH
The VDI Technologiezentrum GmbH is a private company located in Duesseldorf. It has 140
employees, mainly natural scientists, engineers, social and political scientists and economists. The
main focus of company’s work is on
• Research and innovation advancement
• Consulting and moderation of innovation networks
• Technology consulting and innovation assistance
Within the field of “Research and Innovation Advancement”, the VDI Technologiezentrum GmbH
operates as an executive agency of the German Federal Ministry of Education and Research, managing
the national funding programmes in the following thematic areas:
• Optical Technologies
45
Page 46
• Nanotechnologies
• Plasmatechnology
• Security Research
• Electronics.
The VDI Technologiezentrum GmbH also has a vast experience in managing and supporting EU-
activities. The two National Contact Points of Nanotechnology and Security Research are based within
the company. Apart from this, the VDI Technologiezentrum GmbH participates in 12 EU-
projects.VDI will lead the WPD and lead the implementation of the tasks D.2 and D.3
Dr. Oliver Bujok is the senior programme manager of the Nanomedicine section of the WING-
Programme at the VDI Technologiezentrum GmbH. Dr. Bujok is the leader of the national funding
programmes “NanoforLife” (http://www.bmbf.de/de/5063.php) and “Molecular Imaging”
(http://www.vditz.de/mobitech) furthermore he is co-responsible for the national funding programmes
“Nanobiotechnology” (http://www.nanobio.de) and “Bioactive Implants”
(http://www.vditz.de/bioimplant). He holds a PhD in Chemistry from the University of. Bonn. Dr.
Bujok will be the mandated member of the NSC, representing the Federal Ministry of Education and
Research, Germany.
Dr. Joachim P. Kloock is the programme manager of the Nanomedicine part of the WING-Programme
at the VDI Technologiezentrum GmbH. He is co-responsible for the national funding programmes
“Bioactive Implants” (http://www.vditz.de/bioimplant) and “Molecular Imaging”
(http://www.vditz.de/mobitech). Joachim P. Kloock holds a PhD in electrical engineering from the
Technical University of Ilmenau. His main responsibility will be the management of the German calls
launched within the framework of the ERA-Net. He will be a member of the EB, representing the VDI
Technologiezentrum GmbH.
Dr. Olaf Rotthaus is the programme manager of the Nanobiotechnology part of the WING-Programme
at the VDI Technologiezentrum GmbH. He is co-responsible for the national funding programme
“Nanobiotechnology” (http://www.nanobio.de). Olaf Rotthaus holds a PhD in Chemistry from the
University of Essen in collaboration with the Max-Planck-Institute for Radiation Chemistry in
Mülheim, Germany. Before joining the VDI-Technologiezentrum GmbH he worked seven years as a
researcher for the CNRS in France. He will be a member of the EB, representing the VDI
Technologiezentrum GmbH
• P7: Spain - Instituto de Salud Carlos III (ISCIII) / Fundación para la Cooperación y Salud
9/9/2018 draft DOW14012009 V09
Internacional Carlos III (FCSAI)
The Institute of Health Carlos III (Instituto de Salud Carlos III, acronym in Spanish: ISCIII) is one of
the main R&D funding bodies in Spain. It is a national public legally autonomous body created by the
Spanish Parliament’s Act 14/1986, of April 25 (Ley General de Sanidad) under the title VI provisions
(articles 111, 112 and 113) for the scientific and technical support of the National Health System
(formed by the Regional Health Services) and legally entitled to promote research of quality in the
field of Bio-medicine and other Health Sciences. Its Statute is regulated by the provisions of the Royal
Decree 375/2001 of April 6, modified in part by the Royal Decree 590/2005, of May 20. The Fund for
Health Research (Fondo de Investigación Sanitaria, acronym in Spanish: FIS), it’s a legally different
branch for extramural RTD funding within ISCIII (article 7-number 4.3ª provisions of the Royal
Decree 1893/1996, of August 2). It is also responsible to draft the Initiative for Health Research (=
Iniciativa Sectorial de Investigación en Salud) within the R&D&I National Plans of Spain, under the
Chapter IV provisions of the Spanish Parliament’s Act 16/2003, of May 28 (Ley de cohesión y calidad
del Sistema Nacional de Salud). For the Plan 2008 –2011 it is defined as the Strategic Action for
Health Research (= Acción Estratégica de Investigación en Salud) and structured “from the bench to
46
Page 47
the bedside” in basic, translational and applied research in disease oriented, patient oriented,
population oriented, early alert, pharma and health technology assessment research and development.
Most of the budget of ISCIII is public funded (333 M € in 2007 fiscal year, and specifically approved
by the Parliament of Spain in the yearly National Budget Act) and allows to manage thorough ISCIII-
FIS 249 M€ during that year for extramural research funding via a competitive year call for proposals
(projects, networks, non commercial clinical trial, fellowships and job contracts and sabbatical)
published in the Official Gazette of Spain (= BOE) open to health care settings, academia and public
and private non for profit actors, with mission and research track records. Proposals are subjected to
scientific assessment and strategic and opportunity evaluation thorough the respective peer review
processes in a yearly competition, as well as administrative checks. ISCIII is also a funding member
(4.3 M € in 2005) of Fundacioón para la Investigación en Genómica y Proteómica (Genoma España),
that manages the Spanish research initiatives on Genomics, Proteomics and Metabolomics at national
and international co-operation level.
ISCIII participates in several ERA-Nets, such as E-RARE (Coordination of Research of Rare

Diseases), PRIOMEDCHILD (ERA-Net for Priority Medicine for Children), NEURON (ERA-Net for
Neurosciences), Eurocan+plus; and ESFRI, such as ECRIN-IPP (European Clinical Research
Infrastructures Network and biotherapy facilities), BBMRI (Biobanking and Biomolecular Resources
Research Infrastructure) and EATRIS (European Advanced Translational Research Infrastructure in
Medicine). ISCIII also actively participates as funding body in article 169 initiatives such as EDCTP
(European and Developing Countries Clinical Trial Partnership, whose Council´s and European
Parliament´s codecision was approved in 2003), and AAL (Ambient Assisted Living, whose Council
and the European Parliament. codesion is approved in 2008). ISCIII/FCSAI will lead the WP3 of
EuroNanoMed.
The top executive Authority of ISCIII is Prof. Dr. Flora De PABLO Director General. Dr.
Alfredo ANTON RIVAS, the Director of the Fundacion para la Cooperación y Salud Internacional
Carlos III (FCSAI), a branch of the ISCIII with the legal status of a Foundation under the Spanish law,
will act as the legal representative of the ISCIII for this ERA-NET. In addition, Rafael De ANDRES –
MEDINA, Head Department of Docs. and Technical Studies at the Fund for Health Research of the
ISC III, since 2004 will be operationally involved in EuroNanoMed. He was previously Deputy
Director of the Institute for Research on Rare Diseases (Madrid, 2004), the Centre for Toxic Oil
Syndrome and Rare Diseases Research (Madrid, 2002-2003), the National Centre for Fundamental
Biology (Majadahonda, 1997-2001) and the National Center for Cell Biology and Retroviruses
(Majadahonda,1991-1996) at the Institute of Health Carlos III (Spain), as well.as National AIDS
Coordinator of Spain (Ministry of Health and Consumers Welfare, Madrid, 1987-1990). Since 1986,
he has actively participated in numerous international Committees.
• P8: France - The French National Research Agency (ANR).
The National Research Agency ANR– founded in 2005, is a research project funding agency. With a
commitment capability of 700 million Euros over three years, in 2005, it complements the recurrent
funding of French research organisations with a funding system based on objectives and projects.
Funded projects are selected after competition and peer review with an independent selection
procedure. The ANR’s programmes target the whole scientific community, both public research
establishments and companies.
This agency funds all science and technology areas via two major families of programmes:
• The “blue sky”, “young researcher” and “excellence chair” programmes, for which the only
selection criterion is scientific excellence, cover all disciplines.
• The thematic programmes correspond to strategic priorities in three major areas: “Energy and
9/9/2018 draft DOW14012009 V09
sustainable development”, “life sciences”, “information science and technologies, nano-science and
47
Page 48
materials”. Projects are selected on the basis of scientific quality as well as strategic and economic
relevance.
For the past two years, more than 10,000 proposals were submitted requiring some 10,000 scientific
experts to evaluate them. French and foreign experts are chosen for their scientific expertise from the
academic and industrial research community. The projects are ranked by a scientific evaluation
committee and then selected by a strategic panel. About 25 % of submitted proposals have been
funded. Thirty percent of ANR budget were devoted to the “blue sky” programme. Approximately
19% of the ANR budget is dedicated to health and biology projects. The setting up of the Agency is in
the frame of the increase of the French research budget. Thus, the commitment capacity of 700 M€ in
2005 will be increased to 825 M€ in 2006; 2007 budget will be of 955 M€.
In Euronanomed, the ANR will be in charge of task B and subtasks B.1.1, B.1.3, B.2.2, B.4.2. The
contribution will be implemented by two departments:
- The Health and Biology department is headed by Dr. Patrick Chaussepied, and is in charge to run
interdisciplinary thematic (National and trans-national programmes (14 in 2007 and 13 in 2008),
allocating yearly about 140 M€ to more than 300 French research teams working in both fundamental
and applied academic laboratories as well as in private companies.
- The Sciences & Technologies for Information & Communication (STIC) departments headed by Dr.
Louis Laurent, and is in charge of the PNANO programme. Robert Plana is the programme manager
of PNANO. This programme was first launched in 2005.
The contact person for ANR is Dr. Véronique Briquet-Laugier, Programme Manager for the Health-
Biology department. Dr. Briquet-Laugier spent three years at UCLA, USA, after her Ph.D., and
completed her “Habilitation à diriger des recherches” in 2006. Dr. Briquet-Laugier joined ANR in
2007, where she is in charge of international programme for the health and biology department, and
involved in several joint trans-national calls (ERA-Nets NEURON, EraSysBio, E-RARE, and bilateral
collaborations with UK and Germany).
• P9: Hungary – (NKTH) /National Office for Research and Technology
The National Office for Research and Technology (NKTH) plays a key role in elaborating and
implementing Hungary's science-, technology- and innovation policies. NKTH was founded in 2004.
The Office is a public body with full powers and independent budget, it is supervised by the Minister
of Economy and Transport.
NKTH provides support for the creation, dissemination and exploitation of new knowledge and
technology. It also promotes the harmonic development of Hungarian national innovation system and
fosters Hungarian participation and advocacy in international networks of science, technology and
innovation. The Hungarian Programme Committee members and National Contact Points are
delegated from NKTH. NKTH participates in several EU projects funded by FP7 such as
ComplexityNet, SEE- ERA-NET, NupNet, CORNET etc.
NKTH will be specifically leading the task C.3 ‘’Dissemination events to draw attention on
EuroNanoMed’’.
Ms. Ágnes Gulyás : head of department for EU and multilateral relations, PC member for “health” and
NCP coordinator has been working at the NKTH since 2002. She graduated at the University of
Economic. (now Corvinus University) as an economist in 2004. Since 2004 she has been graduating
at the Faculty of law of Eötvös Lorand University. She is responsible for the financial issues of FP7
projects and organization of information days and trainings.
Mr. Zsolt Molnár : project coordinator has been working for the National Office for Research and
Technology since 2007. He received his degree at the University of Debrecen, Faculty of Natural
48
Page 49
Sciences in 2003. After he had graduated as microbiologist, he received a Ph. D scholarship at the
Department of Microbial Biotechnology and Cell biology. He investigated morphological,
physiological and gene expression changes in filamentous fungi during his
9/9/2018 draft DOW14012009 V09
Ph. D work. He was applied as research fellow at the Department between 2006-2007. He is
responsible for penning calls for proposals, organising evaluation processes of proposals and
coordinating R&D projects.
• P10: Israel - The Chief Scientist Office, The Ministry of Health (MOH-CSO)
The Israeli Ministry of Health (MOH) is a government ministry and thus a key player in the funding of
biomedical research and health-related research policy in Israel. The MOH, through the research fund
of the Chief Scientist Office (CSO-MOH) is responsible for managing the government's research fund
dedicated to health and disease-linked biomedical research. As a part of its strategic approach to health
and disease-linked research, CSO-MOH supports investigator-initiated research performed in
universities and hospitals in Israel. The annual budget allocated to medical research by the CSO-MOH
(as annually determined by MOH administration) is 1.5 M€. The intensive bio-medical research in
Israel is also supported by various national, bi-national and international funding agencies, most of
which are public. CSO-MOH is also in charge of the bio-ethical regulation in Israel, through the
National Committee for Human Medical Research and the National Committee on Animal
Experimentation. CSMOH is a fully eligible organization to ERA-NET and is a full partner in the
funded SSA-Neuron, ERA-Age, ERA-PathoGenoMics, ERA-SAGE and in the pending ERA-Neuron,
and ERA-RARE.
Dr. Benny Leshem is the Director of the Medical Research Administration at the Chief Scientific
Office of the Ministry of Health. He will represent the CSO-MOH on the NSC of ERA-NanoMed. Dr.
Irit Allon will represent CSO-MOH at the EB of ERA-NanoMed. Mrs Leah Geula will be the
administrative assistant and the Computer and Communication expert of CSO-MOH.
Dr. Benny Leshem:

Dr. Benny Leshem, born in 1946, studied Chemistry and Biochemistry at the Hebrew University,
Jerusalem and got his PhD in 1989 in Immunology at the Lautenberg Center for General and Tumor
Immunology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. He then spent two
years in Minneapolis, MN, USA as a post-doc with Prof. Fritz Bach, working on tumor immunology.
In 1991 he returned to the Lautenberg Center and conducted research in tumor immunology,
specializing in eliciting clones of cytotoxic T cells against leukemia, in conjunction with stem-cell
transplantation, on differentiating between GVL and GVH responses, on immune tolerance and on anti
fungal immune responses. In 1999 he assumed the position of the Director of the Medical Research
Administration at the Chief Scientist Office (CSO) of the Israeli Ministry of Heath (MOH). In this
capacity he is the director of the Research Fund of CSO-MOH. Dr, Leshem partake (ad hoc or as a
permanent member) in research evaluation committees in Israel, in Europe and the US. He represents
CSO-MOH in the steering committees of ERA-Age, ERA-PathoGenoMics, CoCanCPG and Neuron.
Dr. Irit Allon

Dr. Irit Allon, born in 1971, studied Dentistry at the Hebrew University, Jerusalem and received her
DMD in 1995 from the Hebrew University-Hadassah Medical School, Jerusalem, Israel.
She then enlisted to the Israeli Defense Forces (IDF) and served as a dentist and head of several dental
practices during nine years of service. In 2002, she started a specialization programme in Oral
Pathology at the Oral pathology & Oral Medicine department, School of Dental Sciences, Tel-Aviv
University. In 2004, after completing the service in the IDF, she joined the Chief Scientist Office
(CSO) at the Ministry of Health (MOH) as a national coordinator of ERA-NET PathoGenoMics and
ERA-AGE.
Mrs. Leah Geula:
49
Page 50
Mrs. Leah Geula is responsible for all computer, data mining, databases and communication related
aspects at CSO-MOH, including software and hardware support, e-mails, international relations and
correspondence with other countries. She also holds the responsibility for the on-line assistance to
applicants of research grant requests. She performs all computer graphics and computer related
presentation at the CSO-MOH. She is experienced with CSO-MOH international affairs, organizing all
conferences and meetings inside and outside of CSO-MOH, and as the office contact person for all
ERA-NET and OECD related matters.
• P11: Iceland - The Icelandic Centre for Research (RANNIS)
The Icelandic Centre for Research (RANNIS) reports to the Ministry of Education, Science and
Culture. Its mission is to provide professional assistance to the preparation and implementation of
science and technology policy in Iceland. RANNIS serves the Icelandic science community across all
fields of science and humanities.
Its main duties are the following:

• To operate the public competitive funding system for research and technological development,
9/9/2018 draft DOW14012009 V09
including the Research Fund and the Graduate Education Fund, under the Ministry of Industry and
Commerce.
• Provide services and information to the Science and Technology Policy Council and its
committees on scientific research and technology development, nationally and internationally.
• Coordinate and promote Icelandic participation in international cooperation in science and
technology and interact with corresponding agencies and research councils in other countries
• Monitor the resources and performance of R&D, evaluate the results and impact of scientific
research, technical development and innovation and participate in international benchmarking of
the results
• Promote public awareness of research and innovation.
RANNIS will be in charge of the task A.3, where the RANNIS and Pr Mason have a previous
experience.
On the behalf of RANNIS the work will be done by Már Másson, professor in Medicinal Chemistry at
the Faculty of Pharmaceutical Sciences, University of Iceland. Professor Másson has done
Nanotechnology related research since he did his Ph.D., on biosensors, at the Tokyo Institute of
Technology, Tokyo, Japan. Since returning to Iceland, in 1995, he has been involved in research on
cyclodextrin and synthetic polymer based drug delivery systems. He has authored more than 60 papers
on these subjects. Már has been the national representative of the Mirror group for the ETP on
Nanomedicine and has worked as and external consultant for Rannis.
Also assisting in the work will be Katrin Valgeirsdóttir who holds a Ph.D. in Biology and extensive
experience in teaching and basic research at university level. Dr. Valgeirsdottir is a Senior Advisor in
the International Division of RANNIS. She is a national expert and NCP in FP7 Cooperation Theme
1.2 and 4. and NCP in the ERC programme Ideas.
• P12 :Latvia - the Latvian Academy of Sciences (LAS)

LAS is a public body, which conducts on favouring research in the basic and applied sciences,
especially in multidisciplinary research. LAS coordinates national research programmes and
represents Latvia at the ERA-Net projects. Because Latvia is a “young” member of the EU, LAS is
making the policy to harmonise national research with the European priorities. Current annual budget
50
Page 51
of the research is around €2 billion that comes from the government subsidies. The slightly smaller
amount comes from the European and international foundations and sources.
LAS has the ambitions to bring the research more practical. Therefore, the National programmes are
turning to the industry and business needs. Currently the National Programme on Material sciences
includes particularly research for nanomaterials, biomaterials, etc. The results are planed to be in use
by industry and medicine. The programme is planned for extension to the nano medicine field to be
focused on:
• self assembled inorganic-organic nano complexes and drug delivering and diagnostics;
• nanomagnetic systems for treatment and diagnostics;
• nanoparticled labelled endothelial cells;
• nanostructured ferroelectric films and electrical charge functionalized nano layers of the
surfaces for scaffolds;
• molecular imaging positron emission tomography based systems;
• nanostructured biomimetic scaffolds for cardiovascular tissue engineering;
• magnetic-driven endothelization of vascular scaffolds using iron oxide;
• nanostructured biomaterials;
• life cell based biological modeling to explore influence of the novel nanostructured materials,
particles and films on bio objects;
• analysis of microelements in living tissues by use of cyclotron radiation;
• implementation of the research achievements into clinical practice (ionizing radiation and
photodynamic therapy employing radiation absorbing nanoparticles for local dose increment,
nano particles and functionalized nanofilms based endo implants, molecular imaging,
angiography using nano particles, etc. ).
LAS will involve the following staff:

• Prof. Yuri Dekhtyar (Jurijs Dehtjars), the corresponding member of LAS. Prof. Yuri Dekhtyar has
a great experience to participate and coordinate the international and European projects. During
the last years he was the coordinators of the 6FP EC STREP project, European INTAS project,
and International Atomic Energy Agency project . The projects were dedicated to reach the novel
nanostructured biomaterials, nanofilms and application of radiation for medicine. Prof. Yuri
Dekhtyar will collect information on the activities in Latvia and advice the national experts. Prof.
Yuri Dekhtyar will supply information to the activities in Latvia to initiate them with the project
aims.
• Prof. Vladimir Kasyanov, the corresponding member of LAS has a great experience to participate
9/9/2018 draft DOW14012009 V09
at the international, projects. He is the expert in application of nanostructured biomaterials in
medicine and regenerative medicine. Prof. Vladimir Kasyanov will assist Prof. Yuri Dekhtyar in
collection of information and its processing.
• P13: The Netherlands - SenterNovem
SenterNovem is an agency of the Dutch Ministry of Economic Affairs and promotes sustainable
development and innovation, both within The Netherlands and abroad.. SenterNovem offers a wide
spectrum of products and survices that can be used by the government in public-private partnerships.
From developing and dissemintatin knowledge, to monitoring and developing policy instruments and
to managing subsidy schemes in the field of technology, energy, environment, exports and
international partnerships on behalf of a range of Dutch ministries. SenterNovem can act as a full
partner, eg. As programme manager, participant or programme adviser.
Its objective is to make an enduring contribution to the position of the business sector and knowledge
institutions in the Netherlands.
The organisation has 4 offices in The Netherlands: Den Haag, Utrecht, Zwolle and Sittard.
SenterNovem is also the central desk for questions and advice in the core areas mentioned.
51
Page 52
SenterNovem will participate through the Dutch innovation programme “Life Sciences &
Gezondheid” (=Life Sciences & Health). This programme has three “action lines”: closing the
investment gap, increasing (international) cooperation and improving the overall valorization climate
through coordination and joint representation in the sector.
Senternovem will be in charge of the task D.1 and of the subtasks B.1.2 and D.1.2.
Persons in charge of the project: Sandra de Wild-Chardonnens She is a Bachelor of Nutrition and
Dietetics by education and training and is working for SenterNovem since 1997. She has been
National Contact Point and project officer for the European Frameworkprogramme from 1997 till
September 2007. She has major experience in providing information, advise, training and support to
Dutch participants in the Framework Programme and give advise on Management, Life Sciences
issues, IPR, legal issues. Since September 2007 she has been working for the Dutch innovation
program “Life Sciences & Gezondheid” as project officer dealing with the international aspects of the
program. She is also the Program Committee Member on behalf of the Dutch Ministry of Economic
Affairs for the Health theme within the specific programme ‘Cooperation’ and is the Dutch mirror-
group member for the European Technology Platform Nanomedicines. She has participated in the
following EU projects: TRANSTRACC, PARTNERS FOR LIFE, TRAINNET and SMES GO
LIFESCIENCES, SMES GO HEALTH and CPN-YAS-PRD.
• P14: Poland - National Centre for Research and Development (NCBiR)
The National Centre for Research and Development (NCBiR) is a government funded agency. It was
established in July 2007. NCBiR shall fulfill its mission mainly by funding and managing strategic
scientific research and experimental development programmes. The Centre is responsible for
specifying necessary research tasks, choosing organizations (companies, research institutes,
universities) to perform these tasks, supervising their implementation and introduction of the results
into practical application. The key assumption is the outcome of strategic programmes new
technologies or products – shall be implemented and used in economy, health service, administration
or other areas crucial for Polish society.
Encouraging collaboration between researchers and business community is another priority. On one
hand, NCBiR intends to increase scientists’ level of engagement in industry related research. On the
other, the Centre is to encourage entrepreneurs to develop more R&D intensive activity.
The Centre’s tasks also include:
1. supporting commercialization and other forms of transferring the results of scientific
research to the economy;
2. supporting the development of the research staff, including in particular the involvement of
young scientists in the implementation of research programmes;
3. implementation of international mobility programmes for scientists.
The NCBiR will also represent Poland in international undertakings that will perform R&D
activities.
The National Centre for Research and Development is managed by the Director supported by the
Board, which has the advisory role.
NCBiR will be in charge of the task A.2
On behalf of NCBiR the work will be done by Dr Izabela Rzepczynska.
9/9/2018 draft DOW14012009 V09
Dr. I.Rzepczynska, born in 1979, studied Biotechnology, Specialization: Genetic diagnostics at
Poznan’ University of Life Sciences. With the Socrates Erasmus scholarship she was involved in
Research Project: “Identification of experimental design hormonal interactions in vitro in
Arabidopsis”, at University of Ghent, Belgium. During studies she started cooperation with the
52
Page 53
Division of Infertility and Reproductive Endocrinology at the Poznan University of Medical Sciences.
She finished studies with master thesis “Evaluation of hormonal activity of human granulosa cells
cultured in vitro condition”. She got her PhD from the Karol Marcinkowski Poznan University of
Medical Sciences on the thesis: “Evaluation of oxidative stress influence on ovarian theca-interstitial
cells.” During her PhD studies she got the position of Research Scholar, Postgraduate Associate at
Yale University, New Haven, CT, USA. Since the 2007 she has the position of main specialist and
project coordinator in National Centre for Research and Development.
• P15: Portugal :Fundação para a Ciência e a Tecnologia, Portugal (FCT)
Fundação para a Ciência e Tecnologia (FCT) is the Portugal’s main funding agency for research and it
is responsible for following the bilateral and multilateral international agreements in science and
technology.
FCT is a public autonomous institute under the aegis of the Ministry of Science, Technology and
Higher Education. FCT covers all fields of science, from natural sciences to humanities, normally in a
responsive mode, aiming at capability enhancement and research excellence.
FCT’s mission consists in continuously promoting the advancement of scientific and technological
knowledge in Portugal, exploring opportunities that become available in any scientific or
technological domain to attain the highest international standards in the creation of knowledge, and to
stimulate their diffusion and contribution to improve education, health, environment, and the quality of
life and well being of the general public. This mission is mainly accomplished through the financing
subsequent to the evaluation of the merit of proposals presented by institutions, research teams or
individuals in public open calls, and also through cooperation agreements and other forms of support
in partnership with universities and other public or private institutions. Its functiuns are:
• To promote, finance, accompany and evaluate science and technology institutions, programmes,
projects and qualification of human resources;
• To promote and strengthen support infra-structures for scientific research and technological
development;
• To promote the diffusion of scientific and technological culture and knowledge, and their
teaching;
• To stimulate the update, interconnection, reinforcement and availability of science and technology
information sources at the national and international level;
• To ensure international cooperation in the scientific and technological domains.
With a staff of 228 persons, FCT’s budget for 2008 is around 570 million €. Funding is structured
around the following schemes: promotion of training and career development (fellowships,
scholarships, mainly for PhD, Post-doc and PhD in industry), support of centres of excellence
(associated laboratories) and research centres (institutional funding), support to infrastructures,
promotion and development of scientific activity (research projects) and for diffusion of scientific
culture.
FCT’s research programme supports competitive research activities that for evaluation and
management purposes are sub-grouped in thematic areas. NanoMedicine is covered both by Health
Sciences and Exact Sciences and Engineering. The FCT is also involved in the creation of the
International Iberian Nanotechnology Laboratory (INL) from the Portuguese side. This large
infrastructure is being setup in Braga (North of Portugal) with an annual budget of 30M€ (15M€ from
each Member Country). One of the four focus areas of the INL is Nanomedicine. Within this
framework an Iberian call for collaborative projects between Portuguese and Spanish Groups was
launched (2.8M€ budget in two years) on two thematic areas: Nanomedicine, and Environmental
monitoring/Food quality control and safety.
FCT has experience in coordinated actions at national level (join calls with other Ministries) and at the
European level; FCT participates in several ERA-Nets coordinated actions. Moreover, since 2003
Portugal participates on the EDCTP platform, an initiative co-funded by the EU (FP6) that aims to
53
Page 54
9/9/2018 draft DOW14012009 V09
accelerate
malaria andthe development
tuberculosis. of FCT
The new or improved
is also drugs,
involved vaccines
in the and microbicides
NanoSciences ERA-NET, against HIV/AIDS,
NanoSciERA. In
EuroNanoMed, FCT will be task leader for the task B.3.
The key person to be involved in EuroNanoMed on behalf of FCT is Prof. Luís Viseu Melo. Prof. Luís
Viseu Melo graduated in Physics Engineering at the Instituto Superior Técnico (IST), Technical
University of Lisbon, where he obtained a PhD in 1996 on GMR structures and sensors. In 1998 he
started the first Scanning Probe Microscopy (SPM) Laboratory in the country at IST. Currently his
research work concentrates on nanobiophysics applications and on the development of new techniques
based on the SPM. He is currently a Professor at IST and adviser for Nanotechnology at FCT since
2006, where he coordinates the Portuguese Nanotechnology Network PortugalNano.
• P16: Romania - National Authority for Scientific research (ANCS)
ANCS is the specialised organisation of the central public administration applying the strategies and
programmes of the Romanian Government in the field of R&D and responsible with the
implementation and promotion of the 7th Framework Programme in Romania.
ANCS exercises the following functions: a) political - the function to present and harmonise the
political viewpoint regarding the research-development and innovation field; b) strategic - by which it
strategically plans and ensures the elaboration and implementation of the policies in the field of
research-development and innovation; c) administrative - by which it forecasts, plans, assigns,
monitors and evaluates the use of resources for the implementation of the policies in the field; d)
monitors, evaluates and controls the policies in the field of research, development and innovation; e)
elaborates the normative and methodological framework, functional, operational and financial
framework in which the policies in the field are carried out; f) communication both with the other
structures of the public administration and with the civil society and the citizens; g) international co-
operation - which ensures the application of international agreements in the related field and the
promotion of new agreements; h) state authority – which ensures the monitoring and control of the
settlements in its filed; i) representing – which ensures, on behalf of the Government, its
representation in national, regional and international bodies and organizations, as a state authority for
its field.
The statute of National Authority for Scientific Research is settled by the Governmental Decision no.
1449/17th November 2005. ANCS is familiar with European Framework Programmes participating as
partner or coordinator in the following FP6 projects: several completed or ongoing ERA NET projects,
ROMOB, NEURON ERA-NET, HY-CO ERA-NET, INTER-LINK (will start in 2007), ERA-
ENV(completed), LSH-ACC-MENTOR (completed – specific target ACCs) etc.
The members of the ANCS concerned by the Steering committee of EuroNanoMed are :
- Ms. Iulia Cecilia Mihail:. Ms. Iulia-Cecilia Mihail was born in Bucharest and she has studied at the
University of Bucharest, Faculty of Technological Physics, Engineer on Physics- semiconductors
field. Her actual position is at the ANCS in Bucharest. She is holding the position of Director and
Counsellor in the General Department of National and International Programmes. She is in charge of
the management and the co-ordination of bilateral, regional and multilateral cooperation activities,
with emphasis on the EU programmes. In the years before that she worked among others in the
National Agency for Science, Technology and Innovation and the Ministry of Research and
Technology, Bucharest. She has a strong background regarding participation in international
organizations and other ERA-Nets projects where ANCS is part of the Consortium.
- Ms. Elena Dinu Pelin:. Ms. Elena Dinu Pelin was born on July 28,1967. She studied at the University
Politehnica of Bucharest, Faculty of Applied Chemistry and Materials Science. After finishing her
PhD she continued to work as European Integration Counsellor at the National Authority for Scientific
Research. Starting with 2007 until present she is a European Affairs Counsellor at the National
Authority for Scientific Research. In the last 3 years she was handling the specific activities for the
Romanian integration in UE and for strengthening the Romanian participation capacity in the 6 and 7
54
Page 55
Framework Programme (FP6 and FP7). She is a National Contact Person (NCP) for Nanosciences,
nanotechnologies, Materials & new Production technologies (NMP) and Ideas; National representative
in The Programme Committee for the thematic priority NMP in FP6 and FP7; Expert for “Ideas”
Programme in Romania.
• P17: Romania – National Center for Programme Management (CNMP)
CNMP is a public institution, financed from extra-budgetary funds, with the main mission to
lead/coordinate and optimize the activities for management of RD&I programmes and projects.
CNMP coordinates and monitor the following research programmes: International cooperation and
partnership (CORINT), Environmental Science and Technology in Romania (ESTROM), modules in
the CEEX Programme for Research of Excellence: "Biotechnologies", “Information and
communication technologies”, “Promotion of participation to international and European programmes
for research” and “Partnerships in priority domains” within the national plan for RD&I.
9/9/2018 draft DOW14012009 V09
The main activities
for projects of CNMP
in international are to assure
programmes forconsultancy in finding
scientific research, partners anddevelopment
technological establish partnerships
and
stimulation of innovation, efficient monitoring of programmes, financial, technical and scientific
management for the programmes coordinated by CNMP.
The personns involved in EuroNanoMed are:

- Dr. Serban PANAITESCU is the General Director of CNMP. Counselor to the minister of scientific
research between 2002-2004. Since October 2004, Mr. Panaitescu is in charge with the top
management of CNMP. Mr. Panaitescu is involved, as CNMP representative, in several ERA-NET’s
projects.
- Mrs. Speranta RASAN, graduate of the Chemical Engineering Faculty, Bucharest, 1982, has been
involved in the implementation of European Projects under FP5 and FP6. Between 2001-2005, Mrs.
Rasan was the deputy project manager of the Innovation Relay Centre- Romania. Mrs. Rasan gained
expertise in coordination and executive management of European projects. Since November 2006 she
is the Director of the “Cooperation and International Partnership” Programme within CNMP.
- Mrs. Lucia Stefanescu studied at the Romanian-American University, Faculty of European Economic
Integration Studies and she obtained a BA in economy. Now she attends the Project Management
Master courses. Since March 2007 she is an expert, part time, at the National Authority for Scientific
Research (ANCS) to the SEE-ERA.NET project, and contact person for RoMob portal created in the
frame of the ERA-MORE initiative. Also she has experience in bilateral cooperation; she was
involved in organizing the Joint-Romanian-Cypriot Committee on Research and Development and she
is monitoring the bilateral projects. Since May 2008 she is full time employee of CNMP and she will
be involved in management activities coordinated by CNMP.
- Prof. Dan Dascalu is the General Manager (CEO and President of the Board) of IMT-Bucharest
(www.imt.ro). He is also professor at University “Politehnica” of Bucharest, Dept. of Electronics and
Telecommunications and full member of the Romanian Academy (of Sciences). Prof. Dascalu is the
author of two scientific monographs published in UK and author/coauthor of many other publications.
Prof. Dascalu is representing Romania in the Steering Committee of MNT ERA-NET and in the
“mirror group” for the ETP NanoMedicine. He is participating as an expert to the NMP programme
committee (since 2002). He is the coordinator of MINOS-EURONET, FP6 SSA project mainly
devoted to networking in MNT at the pan-European and national scale and is also the coordinator of
the Romanian Nanomedicine Network RO-NANOMED. Dan Dascalu is Editor-en-chief of the
“Romanian Journal for Information Science and Technology” (edited by the Romanian Academy and
listed by Thomson ISI)) and coordinator of a series of books in “Micro- and nanoengineering” (in
English, Publishing house of the Romanian Academy.
- Claudia Roman joined IMT-Bucharest in 2002, working in the Laboratory for Microsystems in
biomedical and environmental applications. She has been developing management activities for
several international and national projects (3 SSA projects in FP6, promoting the cooperation between
Eastern and Western Europe research organizations in micro-nano domain, the Romanian
55
Page 56
Nanomedicine Network RO-NANOMED). She graduated the Faculty of materials science, University
“Politehnica” of Bucharest, has a master in composite materials and she is currently PhD student at the
same university.
• P18: Sweden - The Swedish research Council (SRC)(Vetenskapsrådet)
The Swedish Research Council is a government agency under the Ministry of Education and Science.
With a budget of some € 308 million a year (2006), the Swedish Research Council is the largest single
source of state funding for basic research in Sweden. In 2006 it distributed just over € 32 million for
research in the humanities and social sciences, € 62 million for medical research, € 113 million for
research in natural and engineering sciences, € 14 millions through the Committee for Educational
Science, and € 64 million for research in Research Infrastructures.
The Scientific Council for Medicine: In line with priorities, which it sets on a national basis, the
Scientific Council for Medicine supports research of the highest quality and the best researchers in
Sweden. A characteristic feature of this Scientific Council is that it chiefly operates in “responsive
mode” and therefore has few programmes. The Council promotes research across all areas of medical
science, i.e. in medicine, dentistry, pharmacy and health care sciences. A large share of its research
support has a direct focus on known diseases and health problems. In addition of the research funded
is concerned with clarifying general biological mechanisms, which may be of significance for an
understanding of disease processes and health problems.
Funding: The main funding instruments are project grants, and support to junior scientists and senior
scientists. In addition, international research cooperation, other grants and reports as well as
evaluations are funded. The Scientific Council reviews, evaluates and prioritizes applications in a
transparent manner, open to scrutiny and participation by the research community. Its legitimacy as an
evaluator of medical research in Sweden is based on the confidence it enjoys among researchers and
on the work the Council does in this context. The Scientific Council for Medicine has 19 evaluation
panels with six experts in each. In 2006 the Scientific Council for Medicine received more than 1700
applications in its yearly call for project grants, junior research positions, national post doctoral
positions in Sweden and post doctoral scholarships abroad.
Other activities: Medical research is an international undertaking. Through it’s funding the Scientific
9/9/2018 draft DOW14012009 V09
Council supports international research cooperation, and it is represented in various European research
organizations and collaborates with research councils in other countries. The Scientific Council’s
information and communication activities are, among other things, designed to make its work
transparent and to involve researchers in discussions about the future and the funding of medical
research. The Council, in association with the Swedish medical faculties, publishes the journal
Forskning & Medicin.
In EuroNanoMed, The SRC will lead the Work package A For that purpose the person involved will
be:
- Dr. Karin Forsberg Nilsson is the Deputy Secretary General of the Scientific Council for Medicine at
the Swedish Research Council, and Associate Professor and Group Leader at the Department of
Medical Biochemistry and Microbiology, Uppsala University. Dr. Forsberg Nilsson received her Ph.D.
in 1992, and trained as a post doc at the National Institute of Neurological Disorders and Stroke,
Bethesda, MD. She was an adjunct lecturer at Uppsala University while holding managerial positions
in the pharmaceutical industry between 1998 and 2002. She returned to the university as Director of
Uppsala University Transgenic Facility in 2002 and was appointed Deputy Secretary General at the
SRC in 2004.
56
Page 57
• P19 : Sweden - The Swedish Governmental Agency for Innovation Systems (VINNOVA )
VINNOVA is a State authority that aims to promote growth and prosperity throughout Sweden. Our
particular area of responsibility comprises innovations linked to research and development. Our tasks
are to fund the needs-driven research required by a competitive business and industrial sector and a
flourishing society, and to strengthen the networks that are such a necessary part of this work.The
Government has assigned VINNOVA to
• make Sweden a leading research nation in which research of high scientific quality is conducted
• promote sustainable growth and increased employment by acting to increase competitiveness and
the emergence and expansion of successful companies.
• support research and development work of the highest quality in areas such as engineering,
transport, communications and working life in order to promote renewal and sustainable growth.
• stimulate Swedish participation in European and international R&D collaboration and in the
exchange of experience in the field of innovation.
VINNOVA’s vision: "VINNOVA makes a clear contribution to Sweden’s development as a leading
growth country."
The main activities of VINNOVA are:

• Information and Communications Technology
• Services and IT Implementation
• Biotechnology
• Working Life
• Product Realisation
• Materials
• Transportation
• Cross-sectoral issues
• Knowledge of Innovation Systems
• Strong research and innovation milieus
• Development of the Research Institutes
• Commercialisation
• Research and Innovation in Small Companies
• International Co-operation
The annual budget is about € 200 million (2006) of which about 170 million is distributed to need
driven research.
The person involved in Euronanomed is Katarina Nordqvist: Katarina Nordqvist received her PhD in
molecular biology at Karolinska Institute in Solna Sweden 1992. She then made postdoctoral training
at the National institute of Medical Research, MRC London UK, for two years. She returned to
Sweden and accepted a position as Assistant Professor at Karolinska Institute, which she held to 2001.
Then she joined AstraZeneca and became Head of CNS and Pain control research until she was
offered the position as Head of Biotechnology and Life Science Department at VINNOVA in 2004.
• Partner 20:Turkey - The Scientific and Technological Research Council of Turkey

(TUBITAK)
9/9/2018 draft DOW14012009 V09
TUBITAK is the leading agency for the management, funding and conduct of research in Turkey. It
was established in 1963 with a mission to advance science and technology, to conduct research and to
support Turkish researchers. TUBITAK funds research projects carried out in universities and other
public and private organisations, conduct research on strategic areas, develops support programmes for
public and private sectors, publishes scientific journals, popular science magazines and books,
57
Page 58
organises science and society activities and supports undergraduate and graduate students through
scholarships. It is a governmental body which operates under the fold of the Prime Ministry with
adequate administrative and financial autonomy. The Council’s decision-making body is the Science
Board, composed of the President and 12 members. The President, as the person of the Science Board,
implements its decisions and is the head of the entire administration.
TUBITAK is also the national coordinating body of the EU Framework Programmes (FP); by its
department “EU Framework Programmes National Coordination Office” (TUBITAK NCO).
TUBITAK organises info-days, conferences and brokerage events to raise the awareness about EU
FPs. Covering all the FP7 areas, Turkish NCPs are working full-time in this office. TUBITAK also
supports Turkish researchers in the development phase of the projects. There are several support
programmes for FP7 such as; travel support, coordinator award, university – industry partnership
promotion award, consortium agreement support and pre-proposal check support. TUBITAK NCO has
been involved in FP6 as a coordinator in 2 SSA projects, and partner in 25 SSA projects. TUBITAK
NCO continues participating to the relevant projects also in FP7, in all priorities.
TUBITAK also has international Relations with ESF, EUREKA, COST, BSEC, ECO, European
Commission, EU 6th Framework Programmes, NATO (SfP & CCMS), OECD, United Nations,
UNDP, UNESCO.
The main tasks of TUBITAK are to determine Turkey’s science and technology policies and to
support, encourage and coordinate scientific research. It establishes and operates special institutes to
conduct research and development activities geared to the targets of the economic development plans
and to the priorities set by the Science Board. It funds research projects carried out in universities and
other public and private organisations, conduct research on strategic areas, develops support
programmes for public and private sectors, publishes scientific journals, popular science magazines
and books, organises science and society activities and supports undergraduate and graduate students
through scholarships.
Calls for proposals are made three times a year. Ordinary scientific and technical research proposals
are submitted to one of the nine committees, as appropriate for the research area. Proposals on
nanomedicine are evaluated mostly by health sciences committee. Applications for special projects are
made directly to the Council. There is no upper financial limit for support.
Evaluation of the proposals is performed by panels composed of researchers in specific scientific

fields of interest (e.g. genetics, molecular biology, medicine, pharmacology, depending on the
proposals received in that particular call). A panel is typically composed of 5-6 persons who evaluate
10-15 proposals in their own field. Each proposal is reviewed by 2-3 members. The members meet to
discuss and finalize the applications.
TUBITAK is partner in the consortium, and will be specifically in charge of leading the task E.3. The
persons invoved in the project are:
• Ms. Melike SEVIMLI: Completed her university education at Middle East Technical University
(M.E.T.U.), Ankara, Department of Food Engineering. She has a master degree on Food
Engineering and a Masters of Busness Administraion degree from the same university (M.E.T.U.).
She has been working at the EU Framework Programmes Unit, TUBITAK, since December 2006
as a Scientific Programmes Assisstant Expert. She has experience in conducting coordination and
support projects, some of which are SMEs Go Health, E-Rare and Meda go to Europe.
• Ms. Melis YURTTAGUL: Got her B.Sc. degree in Chemical Engineering at Middle East
Technical University of Ankara, Turkey in 1999. Between 1999-2004, she’s worked as R&D
Engineer in building chemicals & materials sector and taken M.Sc courses in Biotechnology.
Since 2004 she has been working in TUBITAK EU Framework Programmes National
Coordination Office. She is engaged in the creation and structuralisation of “Turkish Research
Area” and worked in KBBE, SME and JRC. She has experience in conducting coordination and
support projects, some of which are Trainnet Future, Animal Science, Rural Etinet, Tr-Access.
She is one of the two coordinators of Turkish Mobility Network (TR-MONET) Project and ERA-
MIND (ERA-Mobile Researchers in Industry) Project.
58
Page 59
9/9/2018 draft DOW14012009 V09
• P21: Lithuania – Science Council of Lithuania (LSC)
Science Council of Lithuania is a consulting body to the Seimas (Parliament) and the Government in
the studies, research and experimental development policy areas. Established in 1991 the Science
Council of Lithuania was and still remains an initiator or an evaluator of all the most important
legislative proposals in the field of the Lithuanian science and studies system. The main aims of the
Council are to seek that this system would efficiently develop studies, scientific research and
experimental development projects which are significant to the State economy, social development
and international co-operation, and contribute to the creation of intellectual services and science-
oriented high-tech production as well. The Council participates in drafting the legal acts related to
Lithuanian science and studies system; considers the drafts of the legal acts in public and submits
modifications compiling the view of the academic community. Moreover, the Council presents the
proposals on projects of the establishment, reorganisation or liquidation of science and studies
institutions, the proposals on the guidelines of their major research activities and the proposals on
other issues related to the science and studies system.
Within the frame of its currently running generic programmes focusing the support to innovative
research projects, the Science Council of Lithuania has the capability and the willingness to support
Nanomedicine activities and projects. In addition the Science Council of Lithuania is preparing a
National Research Programme entitled Chronic Noncommunicable Diseases in which investigation
and applications of nano methods in medicine are designed. This programme, planned to be approved
and established in the coming months will be more suitable to specifically support the Nanomedicine
projects that are expected within the frame of the EuroNanoMed ERA-Net initiative. Taking part to
this initiative will really help Lithuania in developing best practices in designing and managing
programmes in the field, and will highly promote the integration in the European research area, of our
national Nanomedicine community of actors.
In EuroNanoMed, The LSC will specifically be in charge of the Task E.2. For that purpose the two
key persons involved will be:
Prof. Habil.dr. Ricardas Rotomskis – expert of Science Council of Lithuania for national funding
programmes; expert of Lithuanian State Science and Studies Foundation for programmes dedicated to
high-tech R&D; Professor and Senior researcher in Vilnius University Quantum electronic department
and the Head of Laboratory of Biomedical physics; member of Mirror Group of the European
Tecnhnology platform “NanoMedicine” representing Lithuania; elected member of the Council of the
Lithuanian National technology platform “Nanomedicine”
Prof. Eugenijos Butkus – was appointed the Chairman of the Science Council of Lithuania in 2003,
and the latter was transformed into the Research Council in 2008, he was reappointed as the Chairman.
E. Butkus is an Editor of the Central European Journal of Chemistry and a member of the Editorial
board of the Lithuanian journal of Chemistry. He is an expert member of the evaluation of the research
institutes and programmes as well as university study programs. He is a member of the ERC Ideas
programme committee.
• P22 : Veneto region – Economic development, research and innovation Directorate
The Veneto Region is one of the 20 Italian regional Public Authorities, having its own statute, powers
and functions, under the Italian Constitution principles. The activity of the regional administration
goes from planning to implementing laws and programmes at regional level. Concerning the R&D
matters, Veneto Region created in 2005 a special Department on R&D with the general aim to reach
the 3% of GDP in research and development. The Department, in cooperation with majors Regional
stakeholders (Veneto Innovazione, Universities, Chambers of Commerce), aims at facilitating
enterprises’ access to the scientific and technological infrastructures; developing industrial research
initiatives; managing facilitated loans (CIPE grants for Research); overseeing the VII Framework
Programmes opportunities. Finally, a special regional law on Research and Development entered into
59
Page 60
force in 2007, whose overall aims are the promotion of the R&D, Technology Transfer and Innovation
in the production system, with a particular attention on the link between Research and Industry. In
general, Nanotechnology research is very advanced in Veneto Region, which is at the centre of the
first national Nanotechnology cluster, with strong scientific and productive competences, along with
great application potentials in its industrial environment. Veneto Region has so far funded and
managed regional actions for the development of nanotechnologies, which include Nanomedicine,
with a budget of nearly 54 M €. A regional plan on nanotechnologies, including Nanomedicine, will
be implemented from 2009 and will replace the former actions which are ending. With regard to the
EuroNanoMed project participation, the regional programme will be managed by a regional agency,
Veneto Nanotech, which will be responsible under the supervision of the Veneto region, which is the
programme owner.
NADIA GIARETTA: Head of the office and in charge for managing the Veneto region resources for
Research and Innovation within the Department for Economic Development, Research and
9/9/2018 draft DOW14012009 V09
Innovation. Officer in the Brussels Representation of the Veneto Region ”Co-ordination and
information, studies and projects” Office From 1999 to 2003. Head of the office – Economic profile,
responsible for the Development Regional Plan within the Planning Department. Responsible for
regional activities planning processes and definition of the instruments and methodologies for
monitoring and assessing the policies for the regional planning implementation.
FRANCESCO RONFINI: Lawyer working as senior adviser on European law and policies. As the
Veneto Region representative in Brussels, he entrusted with the activities of the European Council and
with European process decision making in the field of economic, research and innovation policies.
Charged to facilitate and assess the implementation of the EU legislation and Programmes in the field
of R&I. Editor of reports on the development of EU policies with particularly regard to the following:
Research and Development, Public Health and Social Affairs. Coordinator of projects leaded by
Veneto Region under EU Programmes.
• P 23: Veneto region - Veneto Nanotech scpa
The Veneto Nanotech (http://www.venetonanotech.it) is a company established in the 2003 by the

Universities of Padua, Venice and Verona as well as by the Veneto Region in cooperation with the
Italian Ministry of University and Research (MIUR), numerous public institutions and private
companies aiming at coordinating the initiatives and at unifying the strategic vision of the Italian
Nanotechnology Cluster. Veneto Nanotech’s goal is to familiarize companies with nanotechnologies
in order to promote process and product innovation as well as the creation of high-tech companies.
Furthermore, Veneto Nanotech aims at fostering and developing private investments in research and
at supporting high-tech centres for the development of research projects and promotion of high-tech
transfer. Veneto Nanotech manages some facilities operating in research activities the following:
(i) Nanofab scarl - Nanofabrication Facility – one of the first Italian research laboratories dealing
with high-tech transfer to private companies. The laboratory’s scientific focus concerns surface
treatments using many deposition methods for new nano-structured and nano-treated materials,
chemical and bio-chemical nanosensors development and microarrays. Nanofab strongly
cooperates with CIVEN, the association of the three Venetian universities (Padua, Venice and
Verona) which guarantees the scientific development and coordination of the academic
activities in the field of nanotechnologies (www.nanofab.it);
(ii) ECSIN - European Centre for the Sustainable Impact of Nanotechnology - is an international
centre for studying the nanotechnology impact on human health and environment and for
evaluating the ethical aspects on the (human) society. It deals mainly with risk assessment for
companies, evaluation on nanoecotoxicology and juridical-sociological research linked to the
use and/or exposition to nanoparticles and/or nanomaterials (www.ecsin.ue);
60
Page 61
(iii) LaNN - Nanofabrication and Nanodevices Laboratory - falls within the framework of a
collaboration strategy among the VN Cluster, the University of Padua and CNR (National
Research Council). The laboratory is focused on the research on bio-nanophotonics devices
nanofabrication in the areas of nems, mems, lab-on-chip, cleantech.
Veneto Nanotech is a company with a multidisciplinary approach with the mission to carry out
research aimed at obtaining nanomaterials and nanoproducts of industrial interest. At present there are
around 50 researchers involved in the different facilities.
Veneto Nanotech will be wwthe workpackage leader of the WPC and taskleadert of the subtask D.1.1
The staff members who will be undertaking the work are:
NICOLA TREVISAN – CEO of Veneto Nanotech

Nicola Trevisan is Chief Executive Officer of Veneto Nanotech ScpA, the Italian cluster of
nanotechnologies. He is also CEO of Nanofab, the Nanofabrication Facility based in Marghera,
Venice and a member of the Board of ADITE, the Italian Association of High Tech Clusters. He has
extensive experience as a consultant in the field of credit guarantee schemes and management in the
international cooperation projects for the financial growth of the SMEs, by Inter-American
Development Bank, European Commission, Italian Minister of External Affairs, Veneto Region,
Industrial Associations and private companies. He holds a Master Degree in administration and
International Finance.
KARINA FINCATI – Senior Researcher

Dr. K. Fincati received her degree in Biochemistry from the National University of Cordoba in
Argentina in 1991. Until 1997 she has worked in biomedical diagnosis with molecular techniques.
From 1998 to 2001 she has carried out activity of research in molecular biology at the Institute for
Genetic Engineering and Molecular Biology (INGEBI) of the University of Buenos Aires. In 2001
she has obtained a Magister of Sciences in Molecular Biology and a Genetic Engineering from the
University Favaloro (Bs.As). From 2002 to 2005 she has worked in the Department of Histology,
Microbiology and Medical Biotechnologies of the University of Padua where she has collaborated in
9/9/2018 draft DOW14012009 V09
the research plans on the development of adeno/retroviral vectors for gene therapy in tumors. In 2005
received her PhD degree in Virology. Since 2005 she is a staff researcher at CIVEN (Coordinamento
Interuniversitario Veneto per le Nanotecnologie) Her activity is focused on the application of
nanotechnology to biological systems, mainly in the development and production of microarrays and
biosensors for biomedical, environmental and agro-food applications.
• Partner 24 :Walloon region - Ministry of the Walloon Region: Directorate general for
Technology, Research and Energy (DGTRE)
Directorate general for Technologies, Research and Energy (DGTRE), belonging to the Ministry of
the Walloon Region, is the legal administration in charge of funding applied research for new
technologies and energy for industries, academia and research centres, as well as of related
international scientific co-operation. It is therefore the key advisory body for the Regional government
authorities involving research and innovation policy. In 2006, the total funding budget of DGTRE
amounts about € 191 millions. The human resources is of approximately 150 employees.
Since more than ten years, the DGTRE has been actively supporting novel research that is related to
the EuroNanoMed topics. In 2002, a "Nanotechnology" programme allowed to support 7 research
projects with over 13 M€ funding. Approximately 8% of DGTRE budget is allocated to
Nanotechnology projects since 2005. On the other hand, programmes related to "Technologies for
medical applications and health" (WALEO 1, 2002, 17 M€ ; WALEO 2, 2005, 31 M€ and WALEO 3,
2008, ongoing) reveal the interest to support this research.
61
Page 62
The most relevant projects supported recently by the DGTRE in the nanomedicine area are:
- TARGAN "Imaging and treatment of tumoral angiogenesis with specific radioactive
nanoclusters", FUNDP-UCL, 2006-2010, 1,4 M€ ;
- NANOTIC "Swarms of intelligent nano-sensors", UCL, 2005-2009, 25M€ ;
- NANOTOXICO "Study of health hazards for three economically interesting types of nanoparticles
for the Walloon Region", FUNDP, 2006-2009, 10 M€.
The main contacts at the DGTRE are Mrs Julie Jasmes, coordinator of ERA-Net initiatives and Mr.
Baudouin Jambe (PhD), Scientific Officer and coordinator of the Nano-initiative.
9/9/2018 draft DOW14012009 V09
62
Page 63
B 2.3 CONSORTIUM AS A WHOLE
B 2.3.1 Contracting partners
The EuroNanoMed consortium is very broad, reflecting the huge interest and the expectations
generated by this EuroNanoMed initiative. It includes 24 partners from 15 countries and 3 regions.
The 18 countries/regions involved are:
• 14 European countries/regions including 5 new EU Member States (Hungary, Latvia, Poland
Romania and Lithuania)
• 4 associated countries (Iceland, Israel, Switzerland and Turkey).
The composition of the consortium appears well balanced in respect to the very significant critical
mass achieved in the field, the specificities of the existing national actors in Nanomedicine and the
complementarities, the nature and the experience of the partners.
• The EuroNanoMed consortium involves both the policy maker level, owning the programmes as
well as the agencies managing the programmes. Except 5 countries/regions, in all the cases the
agencies own and manage the programme. Having these two types of partners on board is an
essential asset for the effectiveness of the Consortium and its capability to make decisions.
• Regarding the mapping of the players in Nanomedicine existing in the different partners, the data
available from diverse sources provide evidence that the consortium:
o Achieve a more than critical mass, representing 80 % of the total European activities in
the field
o Involves really complementary partners to meet the objective of pulling the technology
from research to preclinical and first stages of clinical trials. Some partners (Germany, the
Netherlands, France, Spain, Israel…) have a significant number of private actors (companies,
pharma companies) interested in the field of Nanomedicine while some partners have a large
proportion of academic teams (Germany, Israel, Sweden, Poland, France, Spain, Wallonia,
new members, associated country…) or of clinical teams (Sweden, Switzerland, Germany,...).
• A lot of the partners (Germany, the Netherlands, France, Sweden, Basque region, Spain ...) are
experienced while partnering in other existing Era-net initiatives. Altogether, the coordination
will allow sharing the experience, taking benefit from the lessons learned for a better achievement
of the EuroNanoMed tasks. This will contribute to include in the momentum and on the basis of
the best practices the partners not really used in running such trans-national programmes.
• Co-ordination and co-operation of the national Nanomedicine programmes of the 19 participating
countries/regions comprising a budget envelope amounting approximately 70-90 M€. This
corresponds approximately to 15-20% of the sum of their national/regional budget specifically
dedicated to support Nanomedicine applications.
All partners are committed to take part to the EuroNanoMed planned activities. As example of this
proactive willingness, considering the size limit of 10 Mbytes for this submission file, the letter of
intent from the partners that are not commonly used to participate in ERA-Net programmes are
provided in Annex 2.
B 2.3.2 Sub-contracting
Only the development of a Website for internal and external purpose (WPE) and the optimization of
the existing electronic tools for the call office and submission of the proposals (WPC) are
subcontracted. It corresponds to very technical tasks aiming at setting up tools necessary for the
implementation of the EuroNanoMed activities and requiring a technical competence not available
among the partners.
63
Page 64
9/9/2018 draft DOW14012009 V09
B 2.4 RESOURCES TO BE COMMITTED
In the tables below,

• personnel and any other major costs are identified per beneficiary,
• the costs items are also detailed per workpackage
As the implementation of the EuroNanoMed initiative is divided in two reporting periods corresponding respectively to months 1-18 and to months 19-36, the costs are indicated for
each period.
Resources to be committed per partner during the period 1 (month 1- month 18) of the project
Partner n° Partner n°
Inno MOH- Senter VIN TUBI

CEA ITT SNF BMBF VDI ISCIII ANR NKTH RANNIS LAS NCBIR FCT ANCS CNMP SRC LSC VED
basque CSO novem NOVA TAK
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Personal costs (€) 79633,8 1296,8 16394,4 9438,0 0,0 48650,0 51740,0 30810,0 4725,0 7800,0 24000,0 4400,0 33020,0 14000,0 17120,0 0,0 14600,0 12980,0 5918,0 10850,0 15185,0 1750
Subcontracting (€) 0,0 0,0 7000,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 22000,0
Other direct costs (€) 10000,0 5700,0 7400,0 7400,0 4600,0 38500,0 9600,0 9600,0 19450,0 9200,0 39200,0 7400,0 10700,0 7400,0 9600,0 0,0 7400,0 7400,0 7400,0 15850,0 7400,0 5700
Indirect costs (€) 6274,4 489,8 1665,6 1178,7 322,0 6100,5 4293,8 2828,7 1692,3 1190,0 4424,0 826,0 3060,4 1498,0 1870,4 0,0 1540,0 1426,6 932,3 1869,0 1581,0 52
Lump sum, flat rate
or scale of unit 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Total Budget 95908,1 7486,5 32460,0 18016,7 4922,0 93250,5 65633,8 43238,7 25867,3 18190,0 67624,0 12626,0 46780,4 22898,0 28590,4 0,0 23540,0 21806,6 14250,3 28569,0 46166,0 7971
Requested budget 95908,1 7486,5 32460,0 18016,7 4922,0 93250,5 65633,8 43238,7 25867,3 18190,0 67624,0 12626,0 46780,4 22898,0 28590,4 0,0 23540,0 21806,6 14250,3 28569,0 46166,0 7971
total receipts 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Resources to be committed per partner during the period 1 (month 19- month 36) of the project
Partner n° Partner n°
Inno MOH- Senter VIN TUBI

CEA ITT SNF BMBF VDI ISCIII ANR NKTH RANNIS LAS NCBIR FCT ANCS CNMP SRC LSC VED
basque CSO novem NOVA TAK
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Personal costs (€) 78911,8 778,1 10246,5 8580,0 0,0 50750,0 44980,0 21450,0 4375,0 7400,0 6000,0 4000,0 6985,0 7000,0 16585,0 0,0 2000,0 5900,0 5380,0 3500,0 4900,0 1050,0
Subcontracting (€) 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Other direct costs (€) 5000,0 3500,0 3500,0 3500,0 3500,0 4600,0 4600,0 4600,0 15550,0 4400,0 4400,0 3500,0 5700,0 3500,0 4600,0 0,0 3500,0 3500,0 3500,0 3500,0 3500,0 3500,0
Indirect costs (€) 5873,8 299,5 962,3 845,6 245,0 3874,5 3470,6 1823,5 1394,8 826,0 728,0 525,0 888,0 735,0 1483,0 0,0 385,0 658,0 621,6 490,0 588,0 318,5
Lump sum, flat rate
or scale of unit 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Total Budget 89785,6 4577,5 14708,8 12925,6 3745,0 59224,5 53050,6 27873,5 21319,8 12626,0 11128,0 8025,0 13573,0 11235,0 22668,0 0,0 5885,0 10058,0 9501,6 7490,0 8988,0 4868,5
Requested budget 89785,6 4577,5 14708,8 12925,6 3745,0 59224,5 53050,6 27873,5 21319,8 12626,0 11128,0 8025,0 13573,0 11235,0 22668,0 0,0 5885,0 10058,0 9501,6 7490,0 8988,0 4868,5
total receipts 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Total budget requested for the whole project (reporting period 1 + 2): 1 33
64
Page 65
Repartition of the costs items between the period 1 (Month 1-18) and the period 2 (months 19-36) of the project
WPA WPB WPC WPD WPE
Travel and subsistance
Meeting M3, JTC-1 (EB+ Meeting M4 JTC-1 (Call committee - 1 WPD task leader Meeting M1 ( EAB meeting, 1
Kick Off meeting 1 1 1 1
NSC meeting - 2 days) NSC - 2 days) meetings day CO+ TL E,3)
Meeting M2 - EB meeting (2 Meeting M6, JTC-2 (EB+ Meeting M5 JTC-1 (NSC -Call 1 WPD task leader
1 1 1 2
days) NSC meeting - 2 days) committee - 1 day) meetings
2 WPB task leaders Meeting M7 JTC-2 (Call committee -

Meeting M9 (EB+NSC :1 day) 2 1 2
meetings (Travels) NSC - 2 days)
1 WPB task leaders Meeting M8 JTC-2 (NSC -Call

2 2
meetings (Travels) committee - 1 day)
1 WPC task leaders meetings

1
(Travels)
1 WPC task leaders meetings

2
(Travels)
JTC1 and JTC 2 announcement and

1 and 2
communication (task C3)
Consumables
Workshop WS2 (task A.3): Workshop WS1 (task D.2): Meeting M1 (EAB meeting - 1
travels+ DSA (26*1100) 1 day * 6 experts + NSC chairman
travels+ DSA (26*1100)
+room rent +room rent )
Editing dissemination
documents/leaflets
sub-contract
on-line tools for JTC (web

1 development of the website
submission tool and partnering tool)
9/9/2018 draft DOW14012009 V09
65
Page 66
B3. IMPACT
B 3.1 STRATEGIC IMPACT
Following the different meetings organised when preparing this EuroNanoMed proposal, it becomes
evidence that:
• Each country has taken somewhat different approaches in their national programmes aiming at
supporting industrial RTD in the field. Many member states have their own regional and/or
national programmes on Research and Technological Development (RTD) which provide sub-
programmes to support Nanomedicine research teams.
• However, looking at those programmes from a European perspective, much fragmentation can
be found and despite the existence of some similarities, the overall impact is therefore sub-
optimal. Optimisation of resources and non-duplication of common activities have to be
implemented.
• A lot of efforts should be devoted to promote the trans-national co-operation reinforcing the
innovative European companies, specially the SME’s, in the field of Nanomedicine through the
establishment of partnerships with clinical and academic teams. This is a strategic opportunity, to
move towards harmonisation, optimising the resources and increasing the competitiveness of the
European Nanomedicine field.
• The close collaboration developed with the ETP Nanomedicine (cross-participations to the
respective Boards, one member of the ETP will be in the External Advisory Board, see WP2) will
bring to a shared vision and definition of the needs and of the most relevant and appropriate topics
to be focused by the EuroNanoMed calls.
The impact of the EuroNanoMed project can therefore be considered at different levels.
B 3.1.1 Improve coordination and reduce overlapping and fragmentation in the key
fields of research in Nanomedicine
In line with the EU-policy context, a wide range of regional and national policy initiatives have been
put in place Based on the co-ordination of national RTD programmes supporting partnership
between academic and enterprises and/or hospital research teams, EuroNanoMed will
contribute to stimulate and co-ordinate the co-operation of national/regional RTD programmes.
☞EuroNanoMed will improve the coordination of national programmes in Nanomedicine.

The final deliverable of EuroNanoMed initiative is the “recipe” towards a fully integrated common
joint programme in Nanomedicine. To meet this final goal, adopting a step by step approach based on
the organisation of 2 common joint trans-national calls more and more integrated, it will directly push
the MS’s working together to identify and analyse the major factors that encourage or hinder mutual
opening of national programmes, overcoming the barriers and developing a common programme
together. The key steps to achieve this aim within EuroNanoMed are:
• To bring national administrations working closely together, creating a high level National
Policy maker group (the Network Steering Committee), building mutual understanding and
trust which have a long lasting effect.
• To bring national managers together through the Executive Board
• To define all the procedures, documents, guidelines, practices, etc for the 2 EuroNanoMed
common joint trans-national calls for projects.
66
Page 67
Independently from the success in meeting our final goal, all the intermediary steps will contribute
9/9/2018 draft DOW14012009 V09
per se to reduce the fragmentation or ERA in Nanomedicine. The Nanomedicine players could
prefer, rather than to develop national projects, to apply to EuroNanoMed calls for projects, at
European level in a flexible way. In addition, implementing the selection and the follow up of the
projects will require a sustainable work in common over many years between the funding agencies
(programme managers).
☞ EuroNanoMed is filling an existing gap in the FP7 landscape.

EuroNanoMed in complementing EU direct actions through FP7, filling some gaps, bringing more
cohesion and coherency, not substituting or duplicating existing programmes and lines in the current
FP7 work programmes. The existing ERA-NETs do not include explicitly Nanomedicine as a key
target or have rules that are not really relevant to Nanomedicine projects:
• EUROTRANSBIO is dealing with biotech which is a border to some specific actions of
Nanomedicine. The large majority of the partnering programmes are unable to fund
Nanomedicine topics. In addition the constraint to have 2 SME’s in each project is
inapplicable to the Nanomedicine field which is not mature enough compared to
biotechnology.
• NANOSCIERA topics are exclusively relevant to the basic fundamental research, and
EuroNanoMed will be the following step and the driving force towards application to industry
and patient.
• ERACHEMISTRY, focusing on bottom up research projects on pure Chemical questions.
However some ERACHEMISTRY projects could eventually be interested to find their
application in the Nanomedicine ERA-NET.
• MANUNET is strictly focusing on R&D projects related to the application and practical use of
manufacturing technologies, market oriented,. The project should be bearded by at least 2
independent SME’s.
• MNTERA-NET is heavily focused on nano-scaled materials and their production. Material for
Nanomedicine represents only one out of various subtopic of this ERA-NET and targets on the
technical/medical aspect of Nanomedicine. The Nanomedicine ERA-NET is needed to cope
the needs in the field of Nanomedicine and will interact synergistically in some aspect with
the MNTERA-NET.
• The Innovative Medicine Initiative (IMI) aims at developing new therapeutics,
pharmaceuticals and biomarkers increasing their predictability, their safety and efficiency. The
Nanomedicine ERA-NET will clearly be beneficial for a better “drug ability” of the
therapeutic molecules identified through IMI, providing nano targeted solutions for delivery,
or associated nano devices for diagnostic or regenerative medicine. Synergies and
complementarities are evident and a mechanism for close collaboration should be developed.
• The European Technology Platform in Nanomedicine: the Nanomedicine ERA-NET is clearly
aiming at working in close collaboration with this ETP. The required procedures for the
development of joint actions will be developed.
The creation of EuroNanoMed is complementary to the existing players and will help gaining in
coherency and putting together all the necessary pieces of the puzzle for the development of
innovative therapeutic solutions for the patient and for the development and competitiveness of the
European health industry in line with the European policy 4,5 stressing the importance of solid and
nationally funded research efforts allowing cross-border co-operation between the best researchers
from public and private sectors.
4 COM 2004-338 final: “Towards a European strategy for nanotechnology”

5 COM (2005) 243 final: Nanosciences and Nanotechnologies : an action plan for Europe 2005-2009
67
Page 68
B 3.1.2 To achieve critical mass and ensure a better use of limited resources in the
research fields of Nanomedicine
☞ EuroNanoMed achieves a critical mass of key actors: (to be finalized when the list of partners
will be known)
• The EuroNanoMed consortium represents approximately 85 % of EU Nanomedicine policy and
funding actors broadening the spectrum of potential partnerships. This let us expecting to have a
significant impact on the European Nanomedicine RTD landscape.
• To facilitate the technology transfer from research to companies and patients, there is Need to
have enough academic teams, clinical teams and companies within the consortium. The
EuroNanoMed is gathering all these categories in a sufficient number of actors, taking together the
countries partnering in the EuroNanoMed initiative.
☞A greater impact with EuroNanoMed common Joint trans-national Calls for Project
proposals than the sum of the National ones.
National programmes have difficulties to support Trans-national projects. In the very specific domain
9/9/2018 draft DOW14012009 V09
of Nanomedicine there are too few players on national level and often Nanomedicine is not directly
the focus of national calls and thus is in competition with many other fields. On the other hand the 7th
Framework Programme (FP7) is limited in funding, and many good projects can’t be supported.
EuroNanoMed will create a mechanism to support Trans-national collaborative RTD projects
between academia, companies (especially SMEs) and/or clinical/health care settings in
Nanomedicine, using a bottom up approach, and based on actual needs.
Across the participating countries, including national and trans-national projects, the aggregating
effect would reach an estimate of 40-60 M€/year of public support. This corresponds approximately
to 15-20% of the sum of their national/regional budget specifically dedicated to support
Nanomedicine applications .As a result of the sharing of practices and of the critical mass, it is
expected to have a greater impact with trans-national common joint Calls for Projects than the sum of
the national ones.
The effectiveness of the EuroNanoMed programme would result from the association of three
characteristics, making it unique:
• It is fully dedicated to Nanomedicine,
• it is directly funded by national actors (not the case of the PCRDT programmes).
EuroNanoMed will ensure a co-financing when projects are selected through a peer-
review panel selection together with external anonymous reviewers, according to rules
established in WPB
• It is mainly bottom-up based, favouring the development for patient/person oriented
and/or industry projects.
B 3.1.3 Sharing good practices in implementing common research programmes

EuroNaNoMed will contribute to improvement and harmonisation of the public policies aiming at
supporting collaborative innovative RTD projects between academics, companies/SME and/or
hospital/health care settings.
☞The use of the highest common denominator practices at national level sharing best practices.
• More specifically, EuroNanoMed will function on a step by step approach, after a mapping of
the practices existing in the programmes partnering in the initiative, the analyses will point out
the best practices. Then the applicable practices for EuroNanoMed will be defined and
implemented in the first call. The lessons learned from the call and the continuous systematic
exchange of information will suggest the best ways for improving existing practices for the
second, and later for the 3rd EuroNanoMed call.
68
Page 69
This iterative process will help in meeting the goal not only to share the good practices but to
effectively use these practices thanks to:
- The immediate use of the best practices identified in the organisation of the
EuroNanoMed calls,
- The process implemented successively for the implementation of the 2 to 3
EuroNanoMed calls for projects,
- The calls will be COMMON joint trans-national calls involving most of the
partners at the same time.
• EuroNanoMed contributes to the preparation and use of European standards with respect to:
- The "systematic" approach for compiling and comparing research programmes (i.e.
congruence of terms, standard data formats, software solutions).
- Best practices with regards to programme management and administration as well as
innovation issues in R&D funding.
- To define and validate as a reference of the appropriate tools and procedures for the
selection of multinational projects and for the monitoring and assessment of
multinational procedures.
- To harmonise evaluation practices of public funding bodies in Europe, especially the
common use and precise definition of criteria and terms like e.g. ”scientific
excellence”, technology transfer, market relevance, clinical/public health needs, etc.
- General agreements and principles for trans-national research activities (e.g. rules for
a contractual and legal framework, models for trans-national funding scenarios).
- Consistent IPR arrangements in research funding with possible considerations to
support the harmonisation of the European patent system.
- Dissemination of EMEA applicable standards to Nanomedicine clinical validation
steps within the “nano community”.
☞Implementation of the research projects selected within the EuroNanoMed calls

• The criteria used for the selection of the projects being best practices shared by funding
9/9/2018 draft DOW14012009 V09
bodies, this will contribute to select projects during the international common selection
process, using mainly the excellence and impact criterion.
• Regarding the critical issue of developments of clinical validation steps, the EuroNanoMed
calls will promote the establishment of trans-national networks and groups of academia
and hospitals/ clinical (health care setting and companies working with academic teams.
This will highly contribute to the sharing and dissemination of the good practices applicable
for the preclinical and the clinical validation steps within the whole nano research
community.
In addition, sharing all these practices within EuroNanoMed would be very useful to some new EU
members states for the development of their new national programmes (e.g. Lithuania), in coherency
with the ERA frame.
The collaboration developed with the ETP Nanomedicine, by having one of its members in the EAB,
will contribute to develop a shared vision and definition of the needs and of the most relevant and
appropriate topics to be focused by the EuroNanoMed calls.
69
Page 70
B 3.1.4 To promote trans-national collaborations and generate new knowledge
During the discussions preliminary to the set up of this initiative, and on the basis of the national
programmes requirements, a clear consensus was established regarding the eligibility conditions
within EuroNanoMed calls for projects. Trans-national collaboration is an absolute mandatory.
EuroNanoMed is not promoting but REQUIRING the trans-national collaborations: this one of
the main added value of this initiative, enlarging the field of possibilities for collaborations to the
Europe.
For the national players, EuroNanoMed, mainly a bottom-up based programme, will broaden the
opportunities to participate in collaborative innovative RTD projects. It extends the field of partnership
to all the countries members of the initiative, exploiting the domains of expertise of public researchers,
of clinicians and of private researchers. This access to a very large number of potential partners
will stimulate creativity of the different actors of the field, generating more new knowledge and
knowledge transfer than national projects because of the fostering effect of EuroNanoMed, improving
ambition and quality of the projects submitted:
- Make it easier to find specific competencies and synergies
- Facilitate international collaborations and synergies.
- Facilitate the multidisciplinary, a crucial issue in the field of Nanomedicine.
- Generate more robust, ambitious and structured innovative RTD projects.
Behind, the implementation of the projects, the mid-term expectations are knowledge translation
generated into applications for market and/or patient products.
B 3.2 SPREADING EXCELLENCE, EXPLOITING RESULTS, DISSEMINATING

KNOWLEDGE
The EuroNanoMed Era Network will involve the partners at strategic level (ministries/policy
makers/programme owner) as well as at a more operational level (agencies/programme managers) to
ensure the completion of the different work packages. However, achievement of the programme will
require (i) a close collaboration with some specific stakeholders and (ii) dissemination of information.
B 3.2.1 Collaboration with the European Technology Platform in Nanomedicine
To develop the Work Packages B, C and D, EuroNanoMed needs to collaborate with the ETP
Nanomedicine.
Thus, the EuroNanoMed partners agreed (cf. Consortium Agreement art.III5°) to have one member
of the Executive Board of the European technology Platform in Nanomedicine, designated to
attend the EuroNanoMed EB and NSC meetings as an observer (consultative voice). This ETP
representative will convey to EuroNanoMed the voice of the platform, meaning the position of the
private and public researchers. Vice versa, a representative from the EuroNanoMed consortium will
attend the ETP executive Board as observer (consultative voice). These proposals has been accepted
by the executive Board of the ETP (ExBo 16/10/2007).
Reminding that the policy makers’ members of the EuroNanoMed NSC could use the Mirror
9/9/2018 draft DOW14012009 V09
Group
betweenfrom the ETP toand
EuroNanoMed convey theirwill
the ETP position to the
function boardside.
in both of the
In ETP, the channel
addition of communication
some EuroNanoMed NSC
members are Mirror group members of the ETP.
70
Page 71
B 3.2.2 collaboration with other specific European stakeholders
For the implementation of the work packages B and C it will be essential to specifically exchange with
the following stakeholders:
- 3 ERA-NETS: NanoSCIERA, MNT ERA, and EUROTRANSBIO,
- The European Joint Technology Initiative for Innovative Medicine (IMI)
- The European Society for Nanomedicine ESNAM that issued recently the CLINAM (network
of clinicians working in Nanomedicine).
The EuroNanoMed Co-ordinator and the related WPL will be in charge to conduct on a regular basis
regular discussions/information and communication with these networks.
B 3.2.3 EuroNanoMed website

The dissemination of knowledge is a main activity supported by the 'public level' of the
EuroNanoMed website. It will enable at 'public level' to gather further details on the objectives,
activities and deliverables of the EuroNanoMed initiative, and also facilitate a public participation and
awareness to its activities, specifically regarding the societal issues.
- Sharing and dissemination of consortium knowledge will be done by reports accessible to
any country interested.
- An integrated data base will be created to provide free (not confidential) information on
EuroNanoMed partnering programmes for future partnership of companies or academic or
hospital RTD project. In addition some electronic 'templates' could be downloaded.
- There will be also an easy linking to national programme websites.
B 3.2.4 Contribution to policy development
Within the frame of the achievement of Lisbon strategy and Barcelona objectives, support for
recommendations of the “Nanosciences and Nanotechnologies Action Plan for Europe 2005-
2009” (COM 2005) 243 final is provided by the activities of this EuroNanoMed ERA-NET Initiative:
• Reinforcement of the industrial involvement in collaborative RTD projects in Nanomedicine (Rec.
4.1b),
• stronger interregional co-operation through networking of nanotechnology regions (Rec. 1.2.b),
• Promotion of Nanomedicine R&D activities by raising awareness among the academic and
industry players (Rec. 1.2c.),
• Encouragement and facilitation for the uptake of innovation by private companies
(recommendation 4.2a)., due to its specific conditions for eligibility (Industrial partner mandatory
in all joint common Calls for Projects)
• Contribution to societal debates and issues related to Nanomedicine.
In addition, EuroNanoMed activities will develop from exploiting synergies between existing national
programmes to the design of a common future trans-national European RTD programme in
Nanomedicine, identifying in consistency with the ETP Nanomedicine and the MS’s policy makers
the current and future research and development priorities in the field. This will provide a strong
policy input to the Commission.
With respect to the European policies relating to Nanosciences and nanotechnologies and to enterprise
and SME’s, EuroNanoMed can give sound contributions to achieve the aim of the EC to translate the
European excellence in Nanosciences into commercially viable product and processes, especially in
context with the tasks Making companies more competitive, Improving SME’s growth potential,
Promoting Innovation and Technology Transfer and promoting the European job mobility. Essential
contributions are:
• European Networking of academic laboratories, companies, and hospitals/health care settings,
inducing enterprise/academic and/or clinical teams partnerships;
71
Page 72
9/9/2018 draft DOW14012009 V09
• Strengthening the European competitiveness and Innovation policy by creation of technical

and structural innovations;
• Promoting the mobility of young scientists.
Based on the co-ordination of national RTD for enterprises programmes, the proposed project
is consistent with the policy objective of “strengthening the European Research Area“.
72
Page 86
73
74
75
76
77
78
79
80
81
82
83
84
85

KARINA FINCATI Senior Researcher VenetoNanotech 7ProgrammaQuadro

Caricato da

Informazioni sul documento

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

KARINA FINCATI Senior Researcher VenetoNanotech 7ProgrammaQuadro

Caricato da

Copyright:

Formati disponibili

9/9/2018 draft DOW14012009 V09

Questa è la versione html del file https://bur.regione.veneto.it/BurvServices/pubblica/Download.aspx?name=858_AllegatoA_214544.pdf&type=9&storico=False. Google genera

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

SEVENTH FRAMEWORK PROGRAMME THEME

Grant agreement for: Coordination and support action (ERA-NET scheme)

Annex I - “Description of Work”

Date of preparation of Annex I (latest version): January 12, 2009

Benef Beneficiary name Beneficiary Country/ Date enter Date exit

A.1 Overall budget breakdown for the project 3

B.1.1 Concept and project objective(s) 5

B.1.2 Progress beyond the state of the art 10

B.2.1 Management structure and procedures 37

B3. Potential impact 66

B.3.1 Strategic impact 66

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

A.1.Budget breakdown and project summary

A.1 Overall budget breakdown for the project

A.2 Project summary

Therefore EuroNanoMed targets the creation of a mechanism to support trans-national

A.3 List of beneficiaries

B1. CONCEPT AND OBJECTIVES, PROGRESS BEYOND STATE-OF-

B 1.1 CONCEPT AND OBJECTIVES

B 1.1.1 Nanomedicine: a challenge for Europe

Figure 2: Nanomedicine impact and main research topics.

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

B 1.1.2 Main Objectives and Long Term Vision

The main objective of EuroNanoMed is to foster the competitiveness of European Nanomedicine

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

programmes to support trans-national RTD partnerships between academics, companies, and

B 1.1.3 Strategic Objectives of the EuroNanoMed initiative

The proposed network has the following strategic objectives:

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

Work package D (WPD): Non-technological innovation barriers

• Provide feedback relevant information to WP B

Work package E (WPE): Management and support

B 1.2 CONTRIBUTION TO THE COORDINATION OF HIGH QUALITY

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

• An impulse towards the applications of Nano biotechnology to medicine to accelerate the

B 1.3 QUALITY AND EFFECTIVENESS OF THE COORDINATION

B 1.3.1 Overall strategy and general description:

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

B 1.3.2 Timing of work packages and their components:

☞ Work package C: Implementation of trans-national Call for Projects

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

☞ Work package D: Non-technological innovation barriers

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

B 1.3.3 Work package list / overview:

Work- Work package title Type of Lead Person- Start End

A Systematic mapping of the ongoing COORD P18 16,3 1 34

B Establishment of the framework for the COORD P7 33,5 2 34

C Implementation of Joint trans-national COORD P3 44,3 3 34

D Non-technological innovation barriers COORD P6 27,1 1 36

E Management and support MGT P1 24 1 36

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

B 1.3.4 Deliverables list:

Deliverable Deliverable name WP Lead Estimated Nature (2) Dissem.

A1 Questionnaire for the information exchange (Kick off meeting) A 17 3.3 O PU

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

B 1.3.5 Work package descriptions:

Milestones and expected results

EuroNanoMed - CSA-CA 234811- drafting date 12/01/2009-Version 09

Work package WP B Start date or starting event : month 2

• Subtask B.1.1. Common strategy / roadmap to a common RTD joint trans-national